zidovudine has been researched along with zalcitabine in 660 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 45 (6.82) | 18.7374 |
| 1990's | 501 (75.91) | 18.2507 |
| 2000's | 79 (11.97) | 29.6817 |
| 2010's | 32 (4.85) | 24.3611 |
| 2020's | 3 (0.45) | 2.80 |
| Authors | Studies |
|---|---|
| Lown, JW; Wang, W | 1 |
| Cross, SS; Gunasekera, SP | 1 |
| Cheng, LC; Chou, TC; Fox, JJ; Harada, K; Matulic-Adamic, J; Ren, WY; Takahashi, K; Watanabe, KA; Zeidler, J; Zhu, QY | 1 |
| Montgomery, JA; Riggs, RM; Secrist, JA; Tiwari, KN | 1 |
| Baba, M; Hayakawa, H; Miyasaka, T; Nitta, I; Sakamaki, T; Sekiya, K; Shigeta, S; Takashima, H; Tanaka, H; Ubasawa, M | 1 |
| Corbett, TH; Court, BA; Kessel, D; Phadtare, S; Renis, HE; Zimlicka, J | 1 |
| Aoki, S; Barchi, JJ; Driscoll, JS; Ford, H; Kelley, JA; Marquez, VE; Mitsuya, H; Shirasaka, T | 1 |
| Horwitz, JP; Kessel, D; Meltsner, BR; Palomino, E | 1 |
| Bushnell, DJ; Duncan, IB; Dunsdon, SJ; Hall, MJ; Machin, PJ; Martin, JA; Merrett, JH; Parkes, KE; Roberts, NA; Thomas, GJ | 1 |
| Brankovan, V; Ghazzouli, I; Mansuri, MM; Martin, JC; Sterzycki, RZ | 1 |
| Hua, M; Vince, R | 1 |
| Augustyns, K; Balzarini, J; Blaton, N; De Clercq, E; De Ranter, C; Everaert, D; Janssen, G; Jie, L; Peeters, O; Van Aerschot, A | 1 |
| De Clercq, E | 1 |
| Baba, M; Balzarini, J; De Clercq, E; Hayakawa, H; Miyasaka, T; Tanaka, H; Walker, RT | 1 |
| Baba, M; Balzarini, J; Broder, S; De Clercq, E; Herdewijn, P; Pauwels, R; Vanderhaeghe, H | 1 |
| Chen, MS; Gao, YS; Ghazzouli, I; Lin, TS; McLaren, C; Prusoff, WH | 1 |
| Antonenko, SV; Chentsova, NP; Kukhar, VP; Luik, AI; Poda, GI; Tetko, IV | 1 |
| Knaus, EE; Kumar, R; Wang, L; Wiebe, LI | 1 |
| Boulanger, WA; Chen, W; Cibulski, M; Flavin, MT; Flavin, TM; Greenwood, EM; Hughes, SH; Khilevich, A; Kucherenko, A; Lin, L; Pengsuparp, T; Pezzuto, JM; Rizzo, JD; Sheinkman, AK; Shone, RL; Vilaychack, V; Xu, ZQ | 1 |
| Gam, J; Kim, DK; Kim, HT; Kim, KH; Kim, YW; Lim, J | 1 |
| Breitenbach, JM; Cheng, YC; Drach, JC; Fan, BY; Kern, ER; Ksebati, MB; Lin, JS; Ptak, RG; Qiu, YL; Zemlicka, J | 1 |
| Hatsuya, S; Iwayama, S; Oikawa, M; Okunishi, M; Ono, N; Sekiyama, T; Suzuki, K; Tanaka, Y; Tsuji, T; Uchiyama, M | 1 |
| Buckheit, RW; Flavin, MT; Khilevich, A; Lin, L; Rizzo, JD; Stup, TL; Xu, ZQ; Zembower, DE | 1 |
| Aubertin, AM; Bisagni, E; Dechaux, E; Dollé, V; Grierson, DS; Guillaumel, J; Legraverend, M; Monneret, C; Nguyen, CH; Note, R; Pontikis, R | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Fujii, N; Gotoh, K; Hattori, T; Hiramatsu, K; Kanamoto, T; Kodama, E; Matsuoka, M; Nakashima, H; Omagari, A; Otaka, A; Tamamura, H; Xu, Y; Yamamoto, N | 1 |
| Fujii, N; Hiramatsu, K; Kuroda, Y; Miyamoto, K; Nakagawa, T; Nakashima, H; Oishi, S; Omagari, A; Otaka, A; Tamamura, H; Yamamoto, N | 1 |
| Alam, N; Hong, J; Im, KS; Jung, JH; Lee, CK; Li, F; Liu, Y; Wang, W | 1 |
| Singh, SK; Yadav, A | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lund, KC; Peterson, LL; Wallace, KB | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Behrens, GM; Das, AM; Lücke, T; Schmidt, RE; Stankov, MV | 2 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Li, Y; Liotta, DC; Liu, L; Lutz, S; Soni, PB; Zhang, X | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Chen, H; Jiang, Z; Li, Z; Wang, T; Xiong, Y; Zhang, L; Zhang, P | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Chen, X; Cheng, Z; De Clercq, E; Liu, X; Meng, C; Pannecouque, C; Shao, S; Zhan, P | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
| Gangadhara, KL; Herdewijn, P; Lescrinier, E; Pannecouque, C | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Bingöl Özakpınar, Ö; De Clercq, E; Küçükgüzel, İ; Kulabaş, N; Özsavcı, D; Pannecouque, C; Tatar, E | 1 |
| Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Aubertin, AM; Périgaud, C; Peyrottes, S; Villard, AL | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gao, Q; Gu, Z; Li, X; Parniak, MA; Wainberg, MA | 1 |
| Cannon, D; Furman, PA; Lloyd, RM; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Sommadossi, JP; St Clair, M; Wilson, J | 1 |
| Fauci, AS | 1 |
| Reddy, MM; Sakai, K; Volsky, B; Volsky, DJ | 1 |
| Bolton, V; Carlson, JR; Cohen, SH; Dickover, RE; Donovan, RM; Goldstein, E; Huth, RG; Liu, GZ | 1 |
| Molina, JM | 1 |
| Gallo, JM; Mehta, M; Qian, MX; Swagler, AR; Vishwanathan, CT | 1 |
| Caliò, R; Perno, CF | 1 |
| Brett, CM; Giacomini, KM; Hui, AC; Wu, X; Yuan, G | 1 |
| Boehme, RE; Cameron, JM; Cammack, N; Coates, JA; Marr, CL; Penn, CR; Reid, PJ; Rouse, P | 1 |
| Amari, JV; Brown, PR; Pivarnik, PE; Sehgal, RK; Turcotte, JG | 1 |
| Johnson, VA | 2 |
| Beach, JW; Cannon, D; Choi, WB; Chu, CK; Jeong, LS; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Yeola, S | 1 |
| Kahn, J | 1 |
| Nightingale, SL | 1 |
| Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
| Decker, RS; Hamblet, N; Li, G; Pellegrino, MG; Potash, MJ; Volsky, B; Volsky, DJ | 1 |
| Husson, RN; Pizzo, PA | 1 |
| Hammer, SM; McLeod, GX | 2 |
| Saag, MS | 2 |
| Skowron, G | 2 |
| Chou, TC; Eron, JJ; Hirsch, MS; Johnson, VA; Merrill, DP | 1 |
| Watson, AJ; Wilburn, LM | 1 |
| Garfunkel, AA; Glick, M | 1 |
| Chu, CK; Cretton, EM; Goudgaon, NM; Schinazi, RF; Sommadossi, JP; Xie, MY | 1 |
| Broder, S; Pluda, JM; Yarchoan, R | 1 |
| Boon, GD; Chan, TC; Redmond, R; Shaffer, L | 1 |
| Chou, TC; Hirsch, MS; Johnson, VA; Merrill, DP | 1 |
| Hostetler, KY; van den Bosch, H; van Wijk, GM | 1 |
| Bawdon, RE; Dax, J; Sobhi, S | 1 |
| Foerster, M; Kastner, U; Neubert, R | 1 |
| Bassiakos, Y; Bennett, D; Boota, AM; Fischl, MA; Lai, SH; Meng, TC; Richman, DD; Spector, SA; Wright, B | 1 |
| Töglhofer, W | 1 |
| Moosmann, EB | 2 |
| Lane, HC | 1 |
| Cooper, DA; Danner, SA; Lange, JM | 1 |
| Broder, S; Caliò, R; Cooney, DA; Foli, A; Gao, WY; Hao, Z; Hartman, NR; Johns, DG; Perno, CF; Yarchoan, R | 1 |
| Cameron, JM; Cammack, N; Coates, JA; Jenkinson, HJ; Jowett, AJ; Jowett, MI; Pearson, BA; Penn, CR; Rouse, PL; Viner, KC | 1 |
| Balzarini, J | 2 |
| Keilbaugh, SA; Prusoff, WH; Simpson, MV | 1 |
| Rousseau, F; Sereni, D | 1 |
| Gao, Q; Li, XG; Parniak, MA; Rooke, R; Soudeyns, H; Tremblay, M; Wainberg, MA; Yao, XJ | 1 |
| Goldsmith, MF | 1 |
| Nowak, R | 1 |
| Fischl, MA | 1 |
| Dunnick, JK; Giles, HD; Irwin, RD; Prejean, JD; Sutphin, ME; Thompson, MB | 1 |
| Butler, K; Husson, R; Marshall, D; Pizzo, PA; Roilides, E; Venzon, D | 1 |
| Ayisi, NK; Gupta, SV; Qualtiere, LF | 1 |
| Germolec, DR; Luster, MI; Powell-Oliver, FE; Rosenthal, GJ; Sanders, VM | 1 |
| Cao, W; Fuchs, BA; Germolec, DR; Luster, MI; Munson, AE; Prejean, JD; Rosenthal, GJ; Shopp, G; Thompson, MB; Tomaszewski, JE | 1 |
| Cameron, JM; Coates, JA; Inggall, HJ; Pearson, BA; Penn, CR; Storer, R; Williamson, C | 1 |
| Pinching, AJ | 2 |
| Chimirri, A; Grasso, S; Monforte, AM; Monforte, P; Zappalà, M | 1 |
| Gallo, JM; Qian, MX; Swagler, AR | 1 |
| Baba, M; De Clercq, E; Hirabayashi, K; Ito, M; Mori, S; Sato, A; Shigeta, S | 1 |
| Hirsch, MS | 1 |
| Horgan, J | 1 |
| Li, G; Pellegrino, MG; Potash, MJ; Volsky, DJ | 1 |
| Goto, H; Kimura, S; Oka, S; Shimada, K | 1 |
| Gerber, MA; Lampertico, P; Malter, JS | 1 |
| Mitsuya, H; Pluda, JM; Yarchoan, R | 1 |
| Broder, S; Kageyama, S; Mitsuya, H; Yarchoan, R | 1 |
| Broder, S; Mitsuya, H; Perno, CF; Pluda, JM; Yarchoan, R | 1 |
| Mitsuya, H | 2 |
| Fernández-Cruz, E | 1 |
| Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
| Basham, T; Holdener, T; Merigan, T | 1 |
| Merigan, TC | 2 |
| Mahler, W | 2 |
| Chen, CH; Cheng, YC; Vazquez-Padua, M | 1 |
| Balzarini, J; De Clercq, E; Good, SS; Gosselin, G; Imbach, JL; Puech, F; Rideout, JL | 1 |
| Foth, H; Frijus-Plessen, N; Kahl, GF; Michaelis, HC | 1 |
| Broder, S | 1 |
| Pizzo, PA | 1 |
| Merigan, TC; Skowron, G | 1 |
| Bozzette, SA; Richman, DD | 1 |
| Fischl, MA; Meng, TC; Richman, DD | 1 |
| Broder, S; Yarchoan, R | 1 |
| Oh-hara, T; Satoh, W; Tsukahara, S; Tsuruo, T; Yamazaki, A; Yusa, K | 1 |
| Eriksson, S; Törnevik, Y | 1 |
| Coulston, AM; Dybevik, K; McCorkindale, C; Sucher, KP | 1 |
| Balis, F; Brouwers, E; Butler, K; Eddy, J; Einloth, M; Falloon, J; Hawkins, M; Husson, R; Jarosinski, P; Pizzo, PA | 1 |
| McGowan, J; Merigan, T; Sherwin, S | 1 |
| Hoth, D | 1 |
| Broder, S; Mitsuya, H; Yarchoan, R | 1 |
| Sommadossi, JP; Weidner, DA | 1 |
| Pizzo, PA; Roilides, E; Rubin, M; Venzon, D | 1 |
| Baba, M; Balzarini, J; De Clercq, E; Desmyter, J; Herdewijn, P; Pauwels, R; Schols, D; Snoeck, R | 1 |
| Benveniste, RE; Follis, KE; Tsai, CC | 1 |
| Jeffries, DJ | 1 |
| Chisaka, O; Matsubara, K; Nagahata, T; Tsurimoto, T; Ueda, K | 1 |
| Darby, G; Larder, BA; Richman, DD | 1 |
| Ganser, A; Greher, J; Hoelzer, D; Staszewski, S; Völkers, B | 1 |
| de Noronha, F; Postie, L; Roneker, C; Tavares, L | 1 |
| Fine, RL; Friedmann, RM; Gartner, S; Popovic, M; Skaleric, U; Szebeni, J; Wahl, LM; Wahl, SM; Weinstein, JN | 1 |
| Hotta, T; Inoue, T; Itoh, T; Nagai, Y; Ogura, M; Saitoh, H; Saneyoshi, M; Tomoda, Y; Tsushita, K; Yoshida, S | 1 |
| Hsia, K; Ripley, D; Spector, SA | 1 |
| Blair, PC; Fort, MM; Fuchs, BA; Germolec, DR; Luster, MI; McCay, JA; Munson, AE; Thompson, M; Tomaszewski, JE; White, KL | 1 |
| Balzarini, J; De Clercq, E; Johns, DG; Matthes, E; Meeus, P | 1 |
| Baba, M; Balzarini, J; De Clercq, E; Miyasaka, T; Nakashima, H; Pauwels, R; Perno, CF; Schols, D; Tanaka, H; Walker, RT | 1 |
| Agrawal, KC; Beckman, BS; Gogu, SR | 1 |
| Balzarini, J; De Clercq, E; Desmyter, J; Goubau, P; Herdewijn, P; Pauwels, R; Vandeputte, M; Vanderhaeghe, H | 1 |
| Carson, DA; Kornbluth, RS; Richman, DD | 1 |
| Miller, JL | 1 |
| Baba, M; Balzarini, J; Broder, S; de Clercq, E; Herdewijn, P; Johns, DG; Pauwels, R | 1 |
| Brady, RO; O'Neill, RR | 1 |
| Broder, S; Mitsuya, H | 1 |
| Chou, TC; Coleman, LA; Durno, AG; Hirsch, MS; Kaplan, JC; Paradis, TJ; Schooley, RT; Vogt, MW | 1 |
| Balfour, HH; Henry, K; Thurn, JR | 1 |
| Pardridge, WM; Terasaki, T | 1 |
| Cooney, DA; Gartner, S; Gerrard, TL; Hao, Z; Hartman, NR; Johns, DG; Perno, CF; Popovic, M; Wilson, YA; Yarchoan, R | 1 |
| Brownell, J; Daluge, S; Hua, M; Kiser, R; Lavelle, GC; Lee, FC; Qualls, J; Shannon, WM; Vince, R; Weislow, OS | 1 |
| Caiazzo, T; Donahue, R; Groopman, J; Johnson, M; Molina, JM | 1 |
| Stingl, G; Wolff, K | 1 |
| Walz, B | 1 |
| Demby, L; Issaq, HJ; Mathes, LE; Mellini, DW; Muschik, G; Polas, P; Sams, R | 1 |
| Richman, DD | 2 |
| Broder, S; Collins, JM; Klecker, RW; McAtee, N; Myers, CE; Thomas, R; Yarchoan, RC | 1 |
| Hiraoka, W; Kuwabara, M; Matsuda, A; Sato, F; Tanabe, K; Ueda, T | 1 |
| Allain, JP; Dubinsky, R; Fischl, MA; Klecker, RW; McAtee, N; McNeely, MC; Perno, CF; Thomas, RV; Wills, RJ; Yarchoan, R | 1 |
| Chen, MS; Kinney-Thomas, E; Lin, TS; Prusoff, WH; Schinazi, RF | 1 |
| Offerhaus, L | 1 |
| Broder, S; Matsushita, S; Mitsuya, H; Reitz, MS | 1 |
| Hamamoto, Y; Matsuda, A; Matsui, T; Nakashima, H; Ueda, T; Yamamoto, N | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Portegies, P | 1 |
| Benoit, SL; Eron, JJ; Fallon, MA; Jemsek, J; Kuritzkes, DR; MacArthur, RD; Quinn, JB; Rubin, M; Santana, J | 1 |
| Cauda, R; Donelli, G; Landay, AL; Lucia, MB; Malorni, W; Ortona, L | 1 |
| Carr, A; Cooper, DA; Loewenthal, M | 1 |
| Leibowitch, J; Liotta, DC; Mathez, D; Schinazi, RF | 1 |
| Mitsuya, H; Shirasaka, T | 1 |
| Balfour, HH; Erice, A | 1 |
| Cameron, J; Fang, H; Gao, Q; Goldberg, E; Gu, Z; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Chong, KT; Hinshaw, RR; Pagano, PJ | 1 |
| Connell, EV; Hsu, MC; Richman, DD | 1 |
| Averett, DR; Dornsife, RE; Jansen, R; Koszalka, GW; Parry, NR; Tisdale, M; Tuttle, JV; Van Draanen, NA | 1 |
| Caliendo, AM; Hirsch, MS | 1 |
| Britton, S; Julander, I | 1 |
| Lacey, SF; Larder, BA | 1 |
| Belmonte, A; Gelfand, M; Gu, Z; Nguyen, K; Salomon, H; Wainberg, MA | 1 |
| López-Galíndez, C; Nájera, I; Nájera, R; Olivares, I; Peinado, MA; Perucho, M; Richman, DD; Rojas, JM | 1 |
| Beardsley, T | 2 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
| Harrigan, PR; Kemp, SD; Larder, BA | 1 |
| Kim, B; Loeb, LA | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Farr, SS; Kammerman, LA; Kazempour, K | 1 |
| Stephenson, J | 1 |
| Choo, V | 1 |
| Cheng, YC; Liu, SH; Skalski, V | 1 |
| Dillner, L | 1 |
| Dalakas, MC; Lewis, W | 1 |
| Stretcher, BN | 1 |
| Faust, EA; Gao, Q; Gu, Z; Wainberg, MA | 1 |
| Posteraro, B; Rossolini, GM; Sanguinetti, M; Satta, G | 1 |
| Camponeschi, B; Viora, M | 1 |
| Domanski, MJ; Egan, D; Follmann, DA; Pizzo, PA; Scalise, PP; Sloas, MM; Tucker, EE | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Hoernle, EH; Reid, TE | 1 |
| Chokekuchai, S; Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Kamali, F | 1 |
| Kemp, SD; Larder, BA; Parry, NR; Tisdale, M | 1 |
| Ellis, MN; Felgner, J; Felgner, PL; Gardner, MF; Hostetler, KY; Ricci, J; Richman, DD; Selleseth, DW; Sridhar, CN | 1 |
| Anderson, BD; Kojima, E; Mitsuya, H; Shirasaka, T; Yarchoan, R | 1 |
| Baseler, MW; Foli, A; Saville, MW; Yarchoan, R | 1 |
| Lissen, E | 1 |
| Khoo, SH; Wilkins, EG | 1 |
| Böttger, S | 1 |
| Berry, S; Bozzette, SA; Duan, N; Kanouse, DE | 1 |
| Oh-hara, T; Tsuruo, T; Yusa, K | 1 |
| Back, DJ; Barry, MG; Veal, GJ; Wild, MJ | 1 |
| Krasinski, K | 1 |
| Spector, SA | 1 |
| Abrams, DI | 1 |
| Dormont, J | 1 |
| Dudley, MN | 1 |
| Cohen, J | 2 |
| Bohr, VA; Link, CJ | 1 |
| Carpenter, CC; Cobbs, CG; Holmes, KK; Sande, MA; Sanford, JP | 1 |
| Houston, SC; Ostashewski, PM; Robertson, JA | 1 |
| Klein, HG; Kumar, P; Merritt, S; Sacher, R; Sloand, E | 1 |
| Lancaster, DJ; Lancaster, LL | 1 |
| Fischl, MA; Lai, S; Meng, TC; Resnick, L; Richman, DD; Spector, SA | 1 |
| Abrams, DI; Crane, LR; Goldman, AI; Grodesky, M; Kornegay, S; Korvick, JA; Launer, C; Muth, K; Neaton, JD; Wakefield, S | 1 |
| Grange, JM; Hamedi-Sangsari, F; Malley, SD; Vila, JR | 2 |
| Stretcher, B | 1 |
| Picard, O | 1 |
| Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Strathdee, SA | 1 |
| Hirschel, B | 1 |
| Aziz, N; Cumberland, WG; Fahey, JL; Liu, M; Merigan, T; Skowron, G | 1 |
| Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Allan, JD; Arduino, JM; Collier, AC; Feinberg, JE; Fischl, MA; Goldsmith, JC; Powderly, WG; Stanley, K; Stein, DS | 1 |
| Allen, SJ; Chen, MS; Cherrington, JM; McKee, BH | 1 |
| Auclair, C; Carteau, S; Goulaouic, H; Mouscadet, JF; Subra, F | 1 |
| Lüthy, R | 1 |
| Gao, Q; Gu, Z; Nagai, K; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Morris, DJ | 1 |
| Cass, CE; Huang, QQ; Paterson, AR; Ritzel, MW; Yao, SY; Young, JD | 1 |
| Portet-Brunet, L | 1 |
| Gobert, JM; North, TW; Remington, KM; Zhu, YQ | 1 |
| Bincsik, A; Lane, J; Mayers, D; Otto, MJ; Scarnati, H; Winslow, DL | 1 |
| Volberding, PD | 1 |
| Antoniskis, D; Arezzo, J; Bigley, J; Bozzette, SA; Fischl, MA; Gelb, LD; Gocke, DJ; Grieco, MH; Hirsch, MS; Hyslop, NE; Leedom, JM; Lim, L; LoFaro, ML; McKinley, GF; Merigan, TC; Murphy, RL; Pettinelli, CB; Pottage, JC; Powderly, WG; Ray, G; Reed, N; Richman, DD; Schaumburg, HH; Simon, G; Skowron, G; Soo, W; Spector, SA; Sperber, SJ; Uttamchandani, RB; Zachary, J | 1 |
| Fischl, MA; Follansbee, SE; Frame, PT; Henry, DH; Lalezari, JP; Lieberman, J; Lin, AH; Nauss-Karol, C; Olson, RM; Remick, SC; Salgo, MP; Soo, W | 1 |
| Morse, GD; O'Donnell, AM; Shelton, MJ | 1 |
| Bergé, P; Mildvan, D; Salgo, M; St Clair, M; Starrett, S | 1 |
| Volberding, PA | 1 |
| Magnuson, T; Mourton, T; Toltzis, P | 1 |
| Dalakas, MC; Jay, C; Ropka, M | 1 |
| Cinatl, J; Doerr, HW; Kornhuber, B; Mainke, M; Rabenau, H; Weber, B; Weissflog, A | 1 |
| Arduino, JM; Chung, R; Crumpacker, CS; Hammer, SM; Japour, AJ; Lane, J; Mayers, DL; McLeod, GX; Reichman, R; Wagner, KF | 1 |
| Armbrecht, C; Hengels, KJ; Jablonowski, H; Manegold, C; Mauss, S; Szelenyi, H | 1 |
| Dubin, DT; Farnham, AE; Fitzgibbon, JE; Kim, H; Sperber, SJ | 1 |
| Chow, FP; Hamburger, AW; Ordóñez, JV; Sutton, PA | 1 |
| Mayaud, C | 1 |
| Brun-Vezinet, F; Pépin, JM; Simon, F | 1 |
| Baranowski, E; Kaulen, P; Pham, DT; Wollensak, J | 1 |
| Buckley, TJ; Jatlow, PI; Rainey, PM; Roberts, WL | 1 |
| Anderson, BD; Broder, S; Husson, RN; Kojima, E; Mitsuya, H; O'Brien, MC; Shimada, T; Shirasaka, T; Yarchoan, R | 1 |
| Lang, W; Moss, A; Osmond, D; Page-Bodkin, K; Winkelstein, W | 1 |
| Bucher, GG | 1 |
| Broder, S; Gao, WY; Johns, DG; Mitsuya, H; Shirasaka, T | 1 |
| D'Aquila, RT; Hirsch, MS | 1 |
| Ratner, L; Vander Heyden, N | 1 |
| Costigliola, P; Degrassi, A; Facchini, A; Lisignoli, G; Monaco, MC; Ricchi, E; Toneguzzi, S | 1 |
| Butler, KM; Husson, RN; Mitsuya, H; Pizzo, PA; Shirasaka, T | 1 |
| Arts, EJ; Boulerice, F; Geleziunas, R; Goldman, H; Wainberg, MA | 1 |
| Brawley, O; Broder, S; Cohen, RB; Nguyen, BY; Pluda, JM; Shay, LE; Venzon, DJ; Whitcup, SM; Wyvill, KM; Yarchoan, R | 1 |
| Clumeck, N | 1 |
| Chien, YW; Kim, DD | 2 |
| Cooper, DA; Emery, S | 1 |
| Arts, EJ; Gu, Z; Le Grice, SF; Marois, JP; Wainberg, MA | 1 |
| Brenner, B; Lalonde, R; Mercure, L; Phaneuf, D; Wainberg, MA | 1 |
| Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW | 1 |
| Hui, F; Kavlick, MF; Kojima, E; Mitsuya, H; Pluda, JM; Shirasaka, T; Yarchoan, R | 1 |
| Gataric, N; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Yip, B | 1 |
| Jablonowski, H | 1 |
| Staszewski, S | 1 |
| Baruch, A; Bassett, RL; Collier, AC; Coombs, RW; Corey, L; Facey, K; Friedman, HM; Hooper, C; Jones, M; McAuliffe, VJ; Merigan, TC; Reichman, RC; Schoenfeld, DA; Timpone, J; Whitacre, C | 1 |
| Adams, O; Jablonowski, H; Mauss, S; Willers, R | 1 |
| Acosta, EP; Henry, K; Jochimsen, E | 1 |
| LaCasse, RA; North, TW; Remington, KM | 1 |
| Chambers, DE; Cooper, DA; Crowe, S | 1 |
| Buckheit, R; Decker, W; Elder, C; Grever, M; Hollingshead, M; Malspeis, L; Mayo, J; Roberson, J | 1 |
| Baughman, WL; Massarella, J; Nosbisch, C; Tuntland, T; Unadkat, JD | 1 |
| Detels, R; Graham, NM; Hoover, DR; Mellors, JW; Park, LP; Phair, JP; Saah, AJ; Stein, DS | 1 |
| Cass, CE; Fliegel, L; Lemire, BD; Michalak, M; Penn, AM; Wang, H; Weiner, JH | 1 |
| Brunet, C; Conciatori, M; Courcoul, M; Dhiver, C; George, F; Guillemain, C; Horschowski, N; Sampol, J; Spire, B | 1 |
| Besley, D; Graham, NM; Jacobson, LP; Muñoz, A; Murphy, R; Park, LP; Zucconi, S | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L | 1 |
| Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S | 1 |
| Martin, TC; Southern, PJ | 1 |
| Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD | 1 |
| Bartlett, JA; Benoit, SL; Ehmann, WC; Fallon, MA; Johnson, VA; Quinn, JB; Rubin, M; Self, PL; Sepulveda, GE; Tsoukas, C | 1 |
| Rowe, PM | 1 |
| de Mendonça, JS | 1 |
| Rosenthal, C | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Cass, CE; Yao, SY; Young, JD | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kohli, A; Lange, JM; Larder, BA; Pennington, KN; Schooley, RT; St Clair, MH | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kinghorn, I; Kohli, A; Larder, BA; Nájera, I | 1 |
| Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ | 1 |
| Cox, S; Harmenberg, J; Palmer, S | 1 |
| Andries, K; De Brabander, M; De Crée, J; De Raeymaeker, M; Miller, V; Moeremans, M; Pearce, G; Peeters, M; Rehmet, S; Stark, T; Staszewski, S; Stoffels, P; Van den Broeck, R; Verbiest, W | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Khoo, S; Veal, GJ | 1 |
| Abraham, T; Nusbaum, NJ | 1 |
| Boulton, A | 1 |
| Gerberding, JL | 1 |
| André, E; Bez, G; Bourdillon, F; Delfraissy, JF; Nadal, JM | 1 |
| Ho, DD | 1 |
| Chikami, GK; Piazza-Hepp, TD; Styrt, BA | 1 |
| Abrams, D; Collins, G; Crane, L; Hodges, JS; Loveless, MO; Markowitz, N; Pettinelli, C; Reves, R; Saravolatz, LD; Stein, DS; Thompson, M; Winslow, DL | 1 |
| Corey, L; Holmes, KK | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Albrecht, H; Fenner, T; Greten, H; Lichtenberg, G; Stellbrink, HJ; Thiele, HG; van Lunzen, J; Zöller, B | 1 |
| Averett, DR; Dornsife, RE | 1 |
| Brandi, G; Carnevali, A; Fraternale, A; Magnani, M; Rossi, L; Schiavano, GF | 1 |
| Medlin, HK; North, TW; Phillips, TR; Remington, KM; Zhu, YQ | 1 |
| Marcus, U | 1 |
| Faulds, D; Lea, AP | 1 |
| Canivet, M; Molina, JM; Peries, J; Santillana-Hayat, M; Valla, J | 1 |
| Cohen, LG; Noormohamed, SE | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Ambetima, N; Blanquet, D; Hallard, M; Mathé, G; Morette, C; Orbach-Arbouys, S; Pontiggia, P; Triana, K | 1 |
| Barber, CG; Hogg, R; Montaner, JS; Murphy, C; O'Shaughnessy, M; Phillips, P; Schechter, MT; Srour, LF | 1 |
| Moyle, GJ | 1 |
| Balagué, M; Cabrera, C; Clotet, B; De Clercq, E; Martínez-Picado, J; Puig, T; Romeu, J; Ruiz, L; Schmit, JC; Segura, A; Sirera, G; Tural, C; Vandamme, AM | 1 |
| Baba, M; Hashimoto, KI; Okamoto, M; Shigeta, S; Tsunoda, R | 1 |
| Gries, JM; Jacobson, M; Sheiner, LB; Troconiz, IF; Verotta, D | 1 |
| Zaretsky, MD | 1 |
| Fornairon, S; Idatte, JM; Lesprit, P; Michaut, P; Modaï, J; Nochy, D | 1 |
| Millard, PS | 1 |
| Bechtel, LM; Starich, GH; Whitfield, RM | 1 |
| Brown, KJ; Davis, HD; Grunberg, NE; Morse, DE; O'Donoghue, VA; Popke, EJ | 1 |
| Gatell, JM; Guerra, L; Pérez-Elías, MJ; Santamaría, JM | 1 |
| Antela, A; Parras, F; Podzamczer, D; Ruiz, I | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Bascuñana, A; Laguna, F; Ocaña, I; Pulido, F | 1 |
| Gatell-Artigas, JM | 1 |
| Augenbraun, M; Minkoff, H | 1 |
| Cui, L; Locatelli, L; Sommadossi, JP; Xie, MY | 1 |
| Caruz, A; Leal, M; Lissen, E; Rey, C | 1 |
| Arboscello, E; Ballarino, P; Bogliolo, G; Castello, G; Cerruti, A; Lerza, R; Mela, GS; Mencoboni, M; Pannacciulli, I | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Back, DJ; Barry, MG; Khoo, SH; Veal, GJ | 1 |
| Heins, JR | 1 |
| Bakshi, SS; Boone, G; Britto, P; Capparelli, E; Fowler, MG; Frank, Y; Jimenez, E; Mofenson, L; Pahwa, SG; Rasheed, S; Salgo, M; Schoenfeld, D; Yogev, R; Zimmer, B | 1 |
| Bürgisser, P; Meylan, PR; Pagani, JL; Spertini, F; Weyrich-Suter, C | 1 |
| Costello, CE; Nelson, MR; Walsh, JC | 1 |
| Ammi-Saïd, M; Barlovatz-Meimon, G; Benbrik, E; Bonavaud, S; Chariot, P; Frisdal, E; Gherardi, R; Rey, C | 1 |
| Brizzi, M; Ceccherini-Nelli, L; Forastieri, G; Iuliano, R; Mazzotta, F; Mecocci, L | 1 |
| Bonsel, GJ; Danner, SA; Lange, JM; Reiss, P; van Leeuwen, R | 1 |
| Blanchard, S; Dankner, WM; Hodes, D; McIntosh, K; McNamara, J; Oleske, JM; Salgo, M; Spector, SA; Wara, DW | 1 |
| al-Attar, I; Burchett, SK; Chatis, P; Fuchs, D; Kornegay, J; McIntosh, K; Orav, J; Wachter, H; Zaknun, D; Zaknun, J | 1 |
| Autran, B; Blanc, C; Carcelain, G; Debré, P; Katlama, C; Leibowitch, J; Li, TS; Mathez, D; Tubiana, R | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Roca, B; Simón, E | 1 |
| Chiang, Y; Drake, RR; Govindarajan, R; Hume, SD; Krisa, S; McMasters, R; Munshi, NC; Rechtin, TM; Saylors, RL | 1 |
| Boucher, C; Brun-Vézinet, F; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Loveday, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Kewn, S; Veal, GJ | 1 |
| Baker, J; Böhnlein, E; Junker, U; Kalfoglou, CS; Kaneshima, H; Veres, G | 1 |
| Blaschke, TF; Collier, AC; Gries, JM; Kastrissios, H; Park, K; Sheiner, LB; Squires, K; Vanhove, GF; Verotta, D | 1 |
| Blaschke, TF; Collier, AC; Coombs, R; Gries, JM; Sheiner, LB; Vanhove, GF; Verotta, D | 1 |
| Fischl, MA; Holden-Wiltse, J; Meehan, PM; Meng, TC; Richman, DD; Saag, M; Squires, KE | 1 |
| Becagli, P; Berto, V; Font, M; Martini, N; Messori, A; Tosolini, F; Trippoli, S; Venturini, F | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Di Genova, G; Fattorossi, A; Malorni, W; Rivabene, R; Viora, M | 1 |
| Goudsmit, J; Pals, ST; Reiss, P; Renwick, N; Roos, MT; Sol, CJ; van Leeuwen, R; Wit, FW | 1 |
| Kavlick, MF; Kosalaraksa, P; Mitsuya, H; Yusa, K | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Clauvel, JP; Davi, F; Jouveshomme, S; Mansour, G; Oksenhendler, E | 1 |
| Byington, R; Elbeik, T; Fiscus, SA; Griffith, BP; Hammer, SM; Hughes, MD; Jackson, B; Japour, A; Katzenstein, DA; Lathey, JL; Pi, T; Rasheed, S; Reichman, R; Scott, W | 1 |
| Brettle, RP; Gore, S; Hutchinson, S; Leen, CL; Lewis, S; Morgan, R; Morris, S; Povey, S; Wilson, A | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Maeda, Y; Mitsuya, H; Venzon, DJ | 1 |
| Burt, MS; Mills, RJ; Scott-Lennox, JA | 1 |
| Kavlick, MF; Mitsuya, H; Wyvill, K; Yarchoan, R | 1 |
| Stevens, TP; Watson, WJ; Weinberg, GA | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Bloch, J; Chavance, M | 1 |
| Bridges, EG; Cheng, YC; Dutschman, GE; Gullen, E; Guo, X; Kukhanova, M; Liu, SH | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Baldeweg, T; Catalan, J; Gazzard, BG | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Font, E; Lasanta, S; Rodríguez, JF; Rosario, O | 1 |
| Boucher, CA; Bruisten, SM; Huisman, JG; Loeliger, AE; Reiss, P; Schuurman, R; van Swieten, P; Weverling, GJ | 1 |
| Cammack, N; Dissanayeke, SR; Duncan, IB; Gilbert, SM; Moffatt, AR; Race, E; Rose, JS; Sheldon, JG; Sitbon, G | 1 |
| Clotet, B; Cruceta, A; García, F; Gatell, JM; Leal, M; Mallolas, J; Miró, JM; Pumarola, T; Ruiz, L; Tortajada, C; Vidal, C | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Belec, L; Cotigny, S; Gilquin, J; Gutmann, L; Kazatchkine, M; Matta, M; Piketty, C; Si Mohamed, A; Weiss, L | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| Saag, MS; Schooley, RT | 1 |
| Boirivant, M; Camponeschi, B; Di Genova, G; Quaranta, MG; Viora, M | 1 |
| González-Lahoz, J; Jiménez-Nacher, I; Moreno Celda, V; Rodríguez-Rosado Martínez-Echevarría, R; Soriano Vázquez, V; Valencia Ortega, E | 1 |
| Arnedo, A; Mínguez, C; Olmos, P; Roca, B; Sáez-Royuela, A; Segarra, M; Simón, E; Teruel, C; Usó, J | 1 |
| Coolley, KL; Girard, YA; Hamdan, H; Katzenstein, DA; Levee, DJ; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C | 1 |
| Collier, AC; Coombs, RW; Efron, B; Lawrence, J; Merigan, TC; Schapiro, JM; Speck, R; Winters, MA | 1 |
| Ippolito, G; Puro, V | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Cinatl, J; Doerr, HW; Driever, PH; Gröschel, B; Kabickova, H; Kornhuber, B; Kotchetkov, R; Schwabe, D | 1 |
| Blaschke, TF; Girard, P; Kastrissios, H; Katzenstein, D; Sheiner, LB; Suárez, JR | 1 |
| Blaschke, TF; Hammer, S; Kastrissios, H; Katzenstein, D; Suárez, JR | 1 |
| Fischer, T; Ramadori, G; Schwörer, H | 1 |
| Moyle, GJ; Sadler, M | 1 |
| Aquilina, C; Bonnet, E; Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sailler, L; Sandres, K | 1 |
| Fleury, S; Miedema, F; Otto, SA; Reiss, P; ten Kate, RW; van der Zee, AG; Wisman, GB; Wolthers, KC | 1 |
| Andersson, F; Hatziandreu, EJ; Oleksy, I; Shakespeare, A; Simpson, K; Tosteson, AN | 1 |
| Phillips, L | 1 |
| Flandre, P | 1 |
| Fischer, T; Ramadori, G; Reich, K; Schwörer, H; Vente, C | 1 |
| Barker, C; Moyle, G; Revicki, DA; Stellbrink, HJ | 1 |
| Armitage, P | 1 |
| Djomand, G; Lackritz, EM; Mbidde, E; Weidle, PJ | 1 |
| Cross, A; Dunkle, L; Kelleher, T | 1 |
| Agarwal, RP; Fernandez, M; Han, T; Wang, W; Yo, P | 1 |
| Martin, EM; Mullane, KM; Novak, RM; Pitrak, DL; Pursell, KJ | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Klarmann, GJ; North, TW; Preston, BD; Schinazi, RF; Smith, RA | 1 |
| Avrămescu, C; Balasoiu, M; Radu, E; Turculeanu, A; Voiculescu, C | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Puig, T; Rey, C; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| Albrecht, H; Hufert, FT; Lauer, J; Racz, P; Schneider, C; Stellbrink, HJ; Tenner-Racz, K; van Lunzen, J | 1 |
| Briones, C; Soriano, V | 1 |
| Cauda, R; Citton, R; Donati, KG; Leone, F; Spanu, T; Tacconelli, E; Tumbarello, M | 1 |
| Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Babiker, A; Collins, R; Darbyshire, J; Duncan, W; Foulkes, M; Hughes, M; Peto, R; Peto, T; Walker, A | 2 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Boschini, A; Calista, D | 1 |
| Betensky, RA; Rabinowitz, D; Tsiatis, AA | 1 |
| Buranapraditkul, S; Chuenyam, M; Cooper, DA; Kroon, ED; Kunanusont, C; Lange, JM; Newell, ME; Phanuphak, P; Ruxrungtham, K; Sirivichayakul, S; Ubolyam, S; Ungsedhapand, C; van Leeuwen, R | 1 |
| Fujinaga, M; Holodniy, M; Schulte, M | 1 |
| Babiker, AG; Clarke, JR; Hooker, MH; Kaye, S; Tedder, R; Weber, JN | 1 |
| Knecht, W; Munch-Petersen, B; Piskur, J | 1 |
| García-Lerma, JG; Gerrish, PJ; Heneine, W; Qari, SH; Wright, AC | 1 |
| Cotton, DJ; Currier, JS; Grimes, J; Hammer, SM; Hughes, MD; Katzenstein, DA; Spino, C; Wofsy, CB | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| Albright, AV; Erickson-Viitanen, S; Frank, I; González-Scarano, F; O'Connor, M; Rayner, MM | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Davis, C; Heredia, A; Redfield, R | 1 |
| Back, DJ; Hart, CA; Hoggard, PG; Kewn, S; Khoo, SH; Sales, SD; Sunderland, D | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Copeland, WC; Lim, SE | 1 |
| Harris, R; Kellagher, A; Moyle, GJ; Walker, M; Warburg, M | 1 |
| Hirsch, MS; Yeni, P | 1 |
| Bagnarelli, P; Chauvin, JP; Clementi, M; De Truchis, P; Gorin, I; Katlama, C; Leibowitch, J; Mathez, D; Mills, R; Pialoux, G; Rode, R; Saimot, G; Tubiana, P | 1 |
| Arnó, A; Balaguer, M; Camafort, M; Cervantes, M; Clotet, B; Colomer, J; Gutiérrez, C; Ibáñez, A; Peraire, J; Richart, C; Ruiz, L; Vidal, F; Villalonga, C | 1 |
| Cabrera, C; Clotet, B; Ibáñez, A; Morales, MA; Puig, T; Romeu, J; Ruiz, L; Sirera, G | 1 |
| Antunes, F; Bouza, E; Harris, R; Moyle, GJ; Smith, D; Walker, M; Warburg, M | 1 |
| Mascolini, M | 5 |
| Colvin, R; Haas, G | 1 |
| Gilden, D | 3 |
| Cheng, B | 3 |
| Prescott, LM | 1 |
| James, JS | 8 |
| Poscher, M | 2 |
| Conant, M | 1 |
| Rubin, M | 1 |
| Japour, AJ | 1 |
| Vella, S | 1 |
| Levin, J | 1 |
| King, E | 1 |
| Baker, R | 1 |
| Chang, HE | 1 |
| Torres, G | 4 |
| Smart, T | 5 |
| Boucher, CA | 1 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Alcorn, K | 1 |
| Folkers, G | 1 |
| MacDougall, DS | 2 |
| Cooper, EC | 1 |
| Randall, P | 1 |
| Doepel, L; Folkers, G | 1 |
| García-Díez, A; Jones-Caballero, M; Peñas, PF | 1 |
| Arduino, JM; Collier, AC; Fischl, MA; Spiegelman, D; Stanley, K | 1 |
| Cain, D; Clarke, JR; Erlwein, O; Frater, AJ; Grigg, AR; Hill, CL; McClure, MO; Patton, G; Rosenblum, LL | 1 |
| Bardwell, PD; Sack, SZ; Scharff, MD | 1 |
| Blumoff, K; Garcia-Lerma, JG; Heneine, W; Nidtha, S; Weinstock, H | 1 |
| Blanquet, D; Hage, F; Hallard, M; Mathe, G; Morette, C; Pontiggia, P | 1 |
| Birkus, G; Cihlar, T; Greenwalt, DE; Hitchcock, MJ | 1 |
| Gibbs, JE; Thomas, SA | 1 |
| Babiker, A; Darbyshire, J; Dunn, D; Hooker, M | 1 |
| Bacheler, L; Bazmi, H; Diamond, S; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Hammond, J; Klabe, R; Liotta, DC; Manion, DJ; Mellors, J; Otto, MJ; Pierce, M; Rayner, M; Schinazi, RF; Stuyver, L; Trainor, G; Wu, JT; Zhang, H | 1 |
| Böckenholt, S; Evers, S; Frese, A; Frohne, L; Heese, C; Husstedt, IW; Rahmann, A; Reichelt, D | 1 |
| Baldwin, SA; Cass, CE; Loewen, SK; Ng, AM; Yao, SY; Young, JD | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Domínguez Castellanos, A; Justo Alpañés, E; Orbea Ríos, L | 1 |
| Domingo, E; Mas, A; Menéndez-Arias, L; Vázquez-Alvarez, BM | 1 |
| Bettendorf, DM; Christopherson, C; D'Aquila, RT; Hammer, SM; Katzenstein, DA; Lathey, JL; Tierney, C | 1 |
| Besson, C; Brebion, A; Delaunay, C; Gonin, C; Hermine, O; Panelatti, G; Plumelle, Y | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Izopet, J; Joly, V; Meiffrédy, V; Tamalet, C | 1 |
| Copeland, WC; Lim, SE; Longley, MJ; Ponamarev, MV | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Derse, D; Hill, SA; Lloyd, PA; McDonald, S; Wykoff, J | 1 |
| Agarwal, RP; Fernandez, M; Han, T; Sarkar, M | 1 |
| Casula, M; de Ronde, A; Goudsmit, J; Lange, JM; Reiss, P; Weverling, GJ | 1 |
| Giordani, L; Mattioli, B; Quaranta, MG; Viora, M | 1 |
| Mukai, E | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Back, N; Bakker, M; Berkhout, B; de Ronde, A; Jebbink, MF; Jurriaans, S; Parkin, N; Reiss, P; van der Hoek, L | 1 |
| Baker, SG; Fitzmaurice, GM; Freedman, LS; Kramer, BS | 1 |
| Bouillaud, F; Leibowitch, J; Lesne, A; Leste-Lasserre, T; Mathez, D; Naviaux, RK; Petit, C; Piétri-Rouxel, F; Sonigo, P | 1 |
| Dettrairat, S; Klinbuayaem, V; Kunachiwa, W; Leechanachai, P; Leenasirimakul, P; Sangkitporn, S; Shide, L; Thamlikitkul, V; Wirayutwatthana, NA | 1 |
| Bacheler, L; Koontz, D; Mellors, JW; Parikh, UM | 1 |
| Johnston, E; Kassaye, SG; Katzenstein, DA; Shulman, NS; Winters, MA | 1 |
| Lund, KC; Wallace, KB | 1 |
| Beauvoit, B; Bonnet, J; Deveaud, C; Kirschner, J; Lebrecht, D; Walker, UA | 1 |
| Eklund, H; Mikkelsen, NE; Munch-Petersen, B | 1 |
| Arenas-Pinto, A; Bhaskaran, K; Dunn, D; Weller, IV | 1 |
| Beauvoit, B; Bonnet, J; Deveaud, C; Kirschner, J; Lebrecht, D; Müller, K; Venhoff, AC; Venhoff, N; Walker, UA | 1 |
| Abuin, A; Cucoranu, I; Fields, E; Green, E; Hosseini, SH; Hoying, A; Ivey, K; Kohler, JJ; Lavie, A; Lewis, W; Raper, CM; Russ, R; Santoianni, R; Yang, Q; Zhelyabovska, O | 1 |
| Laclair, DD; McKee, EE; Morris, GW | 1 |
| Balcarek, K; Beauvoit, B; Bonnet, J; Deveaud, C; Kirschner, J; Lebrecht, D; Venhoff, AC; Venhoff, N; Walker, UA | 1 |
| Asif, G; Coats, SJ; Detorio, M; Koontz, D; Mellors, JW; Meteer, JD; Schinazi, RF; Sluis-Cremer, N; Solomon, S; Zhang, HW | 1 |
| Colan, SD; Mittleman, MA; Oleske, JM; Patel, K; Seage, GR; Van Dyke, RB | 1 |
| Dalla Rosa, I; Dexheimer, TS; Gmeiner, WH; Huang, SY; Murai, J; Naumova, A; Pommier, Y | 1 |
| Brul, S; de Boer, R; De Vos, WH; Manders, EM; Smith, RL; van der Spek, H | 1 |
| Arnold, E; Das, K; Martinez, SE | 1 |
| Abad-Carrillo, MA; Álvarez-Ríos, AI; Bernal-Morell, E; Genebat, M; González-García, J; Herrero-Fernández, I; Leal, M; Montero, M; Pacheco, YM; Pulido, F; Rosado-Sánchez, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Fernández, S; Ferrero, M; Martín-Nieves, V; Sanghvi, YS | 1 |
89 review(s) available for zidovudine and zalcitabine
| Article | Year |
|---|---|
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Antibodies, Viral; Antigens, Viral; Aurintricarboxylic Acid; Deltaretrovirus; Deoxycytidine; Foscarnet; Genes, Viral; Glycoproteins; Humans; Interferons; Male; Phosphonoacetic Acid; Retroviridae Infections; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral; Suramin; Thymidine; Transcription, Genetic; Viral Proteins; Virus Replication; Zalcitabine; Zidovudine | 1986 |
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
[New therapeutic trends in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Deoxyadenosines; Didanosine; Dideoxynucleosides; Humans; Poly I-C; Poly U; Randomized Controlled Trials as Topic; Ribavirin; RNA, Double-Stranded; Zalcitabine; Zidovudine | 1992 |
New developments in antiretroviral drug therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; Drug Therapy, Combination; Gene Products, tat; HIV Infections; HIV-1; Humans; Protease Inhibitors; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1992 |
Anti-human immunodeficiency virus therapeutics: now and the future.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV; HIV-1; Humans; Trichosanthin; Zalcitabine; Zidovudine | 1992 |
The use of nucleoside analogues in the treatment of HIV-infected children.
Topics: Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
HIV disease: therapy, related systemic and oral conditions--an update.
Topics: Acquired Immunodeficiency Syndrome; Bacterial Infections; Didanosine; HIV Infections; Humans; Mouth Diseases; Mycoses; Sarcoma, Kaposi; Virus Diseases; Zalcitabine; Zidovudine | 1992 |
Therapy of AIDS and AIDS-associated neoplasms.
Topics: Acquired Immunodeficiency Syndrome; Humans; Lymphoma, AIDS-Related; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1992 |
Current status of therapy for human immunodeficiency virus type 1.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance; HIV Infections; HIV Seropositivity; HIV-1; Humans; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1992 |
[Anti-HIV treatment, today and in the near future].
Topics: Antiviral Agents; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1992 |
[Treatments of human immunodeficiency virus infection. Current developments].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
New developments in dideoxynucleoside antiretroviral therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
HIV/AIDS pathogenesis and treatment: new twists and turns.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Didanosine; Humans; Lymphocyte Depletion; Trichosanthin; Zalcitabine; Zidovudine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Hematologic effects of AIDS therapies.
Topics: Acquired Immunodeficiency Syndrome; Bone Marrow; Dideoxynucleosides; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Colony-Stimulating Factor; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1991 |
Targeted therapy of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; CD4 Antigens; Didanosine; Dideoxynucleosides; Dipyridamole; Drug Synergism; Gene Expression Regulation, Viral; Genes, nef; Genes, rev; Genes, tat; HIV; HIV Protease; Interferon Type I; Organophosphonates; RNA-Directed DNA Polymerase; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1991 |
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance; HIV; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Retroviridae; Reverse Transcriptase Inhibitors; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Tolerance; HIV; HIV Infections; Humans; Infant; Zalcitabine; Zidovudine | 1990 |
Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Protocols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Zalcitabine; Zidovudine | 1990 |
Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
Topics: Clinical Protocols; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Random Allocation; Zalcitabine; Zidovudine | 1990 |
AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Protocols; Drug Evaluation; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1990 |
Dideoxycytidine: current clinical experience and future prospects. A summary.
Topics: Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Targets for antiviral therapy of human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Dideoxynucleosides; Drug Therapy, Combination; Genes, Regulator; HIV; Humans; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1989 |
[Therapy of AIDS].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Dideoxynucleosides; Humans; Opportunistic Infections; Zalcitabine; Zidovudine | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
Update on reverse transcriptase inhibitors in HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Humans; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors; Zalcitabine; Zidovudine | 1993 |
[Reverse transcriptase inhibitors as anti-HIV agents].
Topics: Amino Acid Sequence; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1993 |
Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
Topics: Antiviral Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Didanosine; Double-Blind Method; HIV Infections; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Zalcitabine; Zidovudine | 1995 |
Mitochondrial toxicity of antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Arabinofuranosyluracil; Didanosine; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Humans; Mitochondria; Zalcitabine; Zidovudine | 1995 |
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Topics: Aging; Antineoplastic Agents; Antiviral Agents; Didanosine; Drug Interactions; Guidelines as Topic; HIV Infections; Humans; Phosphorylation; Racial Groups; Sex Characteristics; Stavudine; Zalcitabine; Zidovudine | 1995 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; Pregnancy; Pregnancy Complications, Infectious; Recurrence; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Needlestick Injuries; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1993 |
[Anti-HIV therapy (1987-1994): from nothing to confusion].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1995 |
Controversies in anti-retroviral therapy of adults.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Combination therapy: more effective control of HIV type 1?
Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy for children.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV-1; Humans; Immunity, Cellular; Virus Replication; Zalcitabine; Zidovudine | 1994 |
HIV therapy advances. Pediatric antiretroviral choices.
Topics: Body Weight; Clinical Trials as Topic; Didanosine; Female; Growth; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Future treatment strategies in HIV infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
Topics: Adult; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance; Guidelines as Topic; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1993 |
Management of antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV-1; Humans; Retroviridae Infections; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy for human immunodeficiency virus infection: hope and despair.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Humans; In Vitro Techniques; Zalcitabine; Zidovudine | 1994 |
[Antiretroviral therapy. Current status and perspectives].
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.
Topics: Animals; Antiviral Agents; Dideoxyadenosine; Dideoxynucleosides; Humans; Lamivudine; Purines; Pyrimidines; Retroviridae; Spiro Compounds; Stavudine; Thymidine; Uridine; Zalcitabine; Zidovudine | 1994 |
Perspectives on the use of antiretroviral drugs in the treatment of HIV infection.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Zalcitabine.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; HIV Infections; Humans; Infant; Zalcitabine; Zidovudine | 1993 |
[Therapy of HIV infection with nucleoside analogs].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine | 1993 |
Therapy for human immunodeficiency virus infection.
Topics: Didanosine; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Protease Inhibitors; Zalcitabine; Zidovudine | 1993 |
Current use of anti-HIV drugs in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
Studies of zidovudine in combination with didanosine and zalcitabine.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Safety; Zalcitabine; Zidovudine | 1995 |
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Zalcitabine; Zidovudine | 1996 |
Prophylaxis for occupational exposure to HIV.
Topics: Antiviral Agents; Health Personnel; HIV Infections; Humans; Lamivudine; Occupational Exposure; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Clinical toxicity of antiretroviral nucleoside analogs.
Topics: Animals; Antiviral Agents; Didanosine; Humans; Lamivudine; Mitochondria; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1996 |
ddC (zalcitabine).
Topics: Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Ritonavir.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; CD4-Positive T-Lymphocytes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocyte Count; Randomized Controlled Trials as Topic; Ritonavir; RNA, Messenger; Zalcitabine; Zidovudine | 1996 |
Pediatric HIV infection: a primer for pharmacists.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pharmacists; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Approach to previously treated patients].
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Treatment modification: toxicity management].
Topics: Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hematologic Diseases; HIV Infections; Humans; Muscular Diseases; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Antiretroviral treatment. Present and future of the combinations].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy for pregnant women.
Topics: Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1998 |
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Finding a role for zalcitabine in the HAART era.
Topics: Anti-HIV Agents; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Saquinavir; Zalcitabine; Zidovudine | 1998 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 2000 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 2000 |
Antiretroviral agents.
Topics: Acyclovir; Animals; Antiviral Agents; Carcinogens; Didanosine; Disease Models, Animal; Evidence-Based Medicine; Humans; Intestinal Absorption; Neoplasms; Risk Factors; Tissue Distribution; Zalcitabine; Zidovudine | 2000 |
[Neuromuscular diseases associated with HIV-1 infection].
Topics: Anti-HIV Agents; Cytomegalovirus Infections; HIV Infections; Humans; Neuritis; Neuromuscular Diseases; Peripheral Nervous System Diseases; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Zalcitabine; Zidovudine | 2004 |
106 trial(s) available for zidovudine and zalcitabine
| Article | Year |
|---|---|
[Efficacy and tolerance of dideoxynucleosides in HIV infection].
Topics: Acquired Immunodeficiency Syndrome; HIV Seropositivity; Humans; Zalcitabine; Zidovudine | 1992 |
Therapy of AIDS and AIDS-associated neoplasms.
Topics: Acquired Immunodeficiency Syndrome; Humans; Lymphoma, AIDS-Related; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1992 |
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Topics: Adult; CD4-Positive T-Lymphocytes; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Zalcitabine; Zidovudine | 1992 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Protocols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Zalcitabine; Zidovudine | 1990 |
Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
Topics: Clinical Protocols; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Random Allocation; Zalcitabine; Zidovudine | 1990 |
Nutritional status of HIV-infected patients during the early disease stages.
Topics: Acquired Immunodeficiency Syndrome; Adult; Diet; Double-Blind Method; Energy Intake; Hematocrit; Hemoglobins; Humans; Male; Middle Aged; Nutritional Requirements; Nutritional Status; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1990 |
Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Age Factors; Antigens, CD; CD4 Antigens; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Male; Neuropsychological Tests; Time Factors; Zalcitabine; Zidovudine | 1990 |
Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function.
Topics: Cell Survival; Chemotaxis, Leukocyte; Didanosine; HIV Infections; HIV-1; Humans; Neutrophils; Phagocytosis; Superoxides; Zalcitabine; Zidovudine | 1990 |
FDA expands testing of anti-AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Complex; Antiviral Agents; Clinical Trials as Topic; Didanosine; Humans; Infant; Infant, Newborn; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1989 |
Progress in antiviral drug and vaccine development assessed at international AIDS conference.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Evaluation; Drug Therapy, Combination; Humans; Ribavirin; Thymidine; Viral Vaccines; Zalcitabine; Zidovudine | 1987 |
AIDS. Treatment strategies and the Minnesota AIDS Clinical Trials Unit.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Humans; Opportunistic Infections; Thymidine; Zalcitabine; Zidovudine | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
[Azidothymidine and HIV infection].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Humans; Thymidine; Zalcitabine; Zidovudine | 1987 |
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Topics: Antiviral Agents; Base Sequence; CD4 Lymphocyte Count; Cell Line; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Serial Passage; Zalcitabine; Zidovudine | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Health Status; Humans; Male; Regression Analysis; Severity of Illness Index; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Treatment options in zidovudine intolerance or failure.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Female; Follow-Up Studies; Humans; Male; Survival Rate; Time Factors; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
Topics: CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV; HIV Infections; Humans; Leukocyte Count; Time Factors; Zalcitabine; Zidovudine | 1994 |
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Leukocyte Count; Male; Risk; Zalcitabine; Zidovudine | 1994 |
Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. AIDS Clinical Trial Research Group 047.
Topics: Acquired Immunodeficiency Syndrome; beta 2-Microglobulin; Biopterins; HIV Core Protein p24; Humans; Immune System; Neopterin; Zalcitabine; Zidovudine | 1994 |
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; HIV Core Protein p24; Humans; Lymphocyte Count; Male; Zalcitabine; Zidovudine | 1995 |
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematologic Diseases; HIV Core Protein p24; Humans; Leukocyte Count; Male; Peripheral Nervous System Diseases; Weight Gain; Zalcitabine; Zidovudine | 1993 |
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Topics: Adult; Body Weight; CD4-Positive T-Lymphocytes; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Regression Analysis; Severity of Illness Index; Survival Rate; Zalcitabine; Zidovudine | 1993 |
Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4-CD8 Ratio; Cytomegalovirus Retinitis; Drug Therapy, Combination; HIV Infections; Humans; Incidence; Male; Prospective Studies; Zalcitabine; Zidovudine | 1993 |
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Zidovudine and lamivudine: results of phase III studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Topics: Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Male; Quinolines; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; HIV Seropositivity; Humans; Longitudinal Studies; Male; Proportional Hazards Models; Zalcitabine; Zidovudine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biopterins; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Neopterin; Polymerase Chain Reaction; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Topics: Antigens, CD; Antiviral Agents; CD4 Antigens; Coculture Techniques; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Phenotype; Point Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Topics: Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
Topics: Acetamides; Acetophenones; Adult; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cross-Over Studies; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Pilot Projects; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Rese
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Risk; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Seropositivity; HIV-1; Humans; Kinetics; Male; RNA, Viral; Saquinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; British Columbia; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Prospective Studies; Zalcitabine; Zidovudine | 1996 |
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Viral Load; Zalcitabine; Zidovudine | 1996 |
A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Humans; Regression Analysis; Time Factors; Zalcitabine; Zidovudine | 1997 |
[Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Drug Therapy, Combination; Genotype; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cause of Death; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Infant; Male; Neutropenia; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1997 |
Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biopsy, Needle; CD4 Lymphocyte Count; CD4-CD8 Ratio; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; HIV-1; Humans; Lymph Nodes; Polymerase Chain Reaction; Regression Analysis; RNA Splicing; RNA, Viral; Saquinavir; Single-Blind Method; Viremia; Zalcitabine; Zidovudine | 1997 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
Topics: Adult; Age Factors; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.
Topics: Adolescent; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Male; Zalcitabine; Zidovudine | 1997 |
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; Antigens, Viral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Homeostasis; Humans; Immunologic Memory; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocyte Subsets; Tuberculin; Viral Load; Viremia; Zalcitabine; Zidovudine | 1997 |
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV Infections; HIV-1; Humans; Point Mutation; Prospective Studies; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1997 |
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Disease Progression; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Multivariate Analysis; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Quality of Life; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1998 |
Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Topics: Amino Acid Sequence; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Phenotype; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Giant Cells; HIV Infections; HIV-1; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Probability; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
[Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Saquinavir; Zalcitabine; Zidovudine | 1998 |
A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; Humans; Male; Nevirapine; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1998 |
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Codon; Cohort Studies; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease; HIV-1; Humans; Mutation; RNA, Viral; Saquinavir; Time Factors; Zalcitabine; Zidovudine | 1999 |
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Time Factors; Zalcitabine; Zidovudine | 1998 |
The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality of Life; Reverse Transcriptase Inhibitors; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; RNA, Viral; Thailand; Zalcitabine; Zidovudine | 2000 |
Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Codon; DNA; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2000 |
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; Humans; Liver; Male; Nucleosides; Prospective Studies; Sex Characteristics; Zalcitabine; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Male; Middle Aged; Quality of Life; Zalcitabine; Zidovudine | 1997 |
FDA Committee recommends clearance for HIVID combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Time Factors; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
Merck protease inhibitor trial seeks persons with CD4 count under 50.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Industry; Drug Therapy, Combination; HIV Protease Inhibitors; Hotlines; Humans; Indinavir; Lamivudine; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
New protease inhibitor studies.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
Major study shows AZT monotherapy inferior.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
Treatment for primary infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Controlled Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Placebos; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Agouron starts phase III protease inhibitor studies.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lamivudine; Placebos; Zalcitabine; Zidovudine | 1996 |
Abbott laboratories files New Drug Application for ritonavir.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Double-Blind Method; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
CPCRA 007: preliminary results of combination antiretroviral study.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2001 |
Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; International Cooperation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2001 |
Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 2002 |
Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Evoked Potentials; Female; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Treatment Outcome; Zalcitabine; Zidovudine | 2002 |
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; HIV-1; Humans; Multivariate Analysis; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 2003 |
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Selection, Genetic; Thymidine; Zalcitabine; Zidovudine | 2003 |
Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Topics: Adult; Anti-HIV Agents; Astragalus propinquus; Carthamus tinctorius; Double-Blind Method; Drug Therapy, Combination; Female; Glycyrrhiza; HIV Infections; Humans; Male; Middle Aged; Phytotherapy; Plant Preparations; Thailand; Treatment Outcome; Zalcitabine; Zidovudine | 2005 |
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
Topics: Adult; Anti-Retroviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Receptors, CCR5; Receptors, CXCR4; Zalcitabine; Zidovudine | 2007 |
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 2008 |
473 other study(ies) available for zidovudine and zalcitabine
| Article | Year |
|---|---|
Anti-HIV-I activity of linked lexitropsins.
Topics: Antiviral Agents; Cells, Cultured; DNA, Viral; Drug Design; HIV-1; Moloney murine leukemia virus; Netropsin; Structure-Activity Relationship; Viral Plaque Assay | 1992 |
Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.
Topics: Animals; Antiviral Agents; Isoxazoles; Leukemia Virus, Feline; Magnetic Resonance Spectroscopy; Porifera; Spectrophotometry, Ultraviolet; Tumor Cells, Cultured; Tyrosine; Virus Replication | 1992 |
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
Topics: Antiviral Agents; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; HIV Antigens; HIV-1; Humans; Molecular Structure; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1990 |
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Dideoxynucleosides; HIV | 1992 |
A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
Topics: Antiviral Agents; Cell Line; Cell Survival; HIV-1; Humans; Indicators and Reagents; Molecular Structure; Structure-Activity Relationship; Thymine | 1991 |
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
Topics: Adenosine Deaminase; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Friend murine leukemia virus; HIV-1; HIV-2; Humans; Indicators and Reagents; Leukemia L1210; Mice; Molecular Structure; Nucleosides; Rauscher Virus; Structure-Activity Relationship | 1991 |
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
Topics: Adenosine Deaminase; Antiviral Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV; Kinetics; Prodrugs; Structure-Activity Relationship | 1991 |
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
Topics: AIDS Dementia Complex; Animals; Antiviral Agents; Cell Line; Chemical Phenomena; Chemistry; Chemistry, Physical; Cytopathogenic Effect, Viral; Dideoxynucleosides; HIV; Humans; Kinetics; Molecular Structure; Phosphorylation; Pyrimidine Nucleosides; Rabbits; Stavudine; T-Lymphocytes; Thymidine Kinase; Thymus Gland; Zidovudine | 1990 |
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).
Topics: Antiviral Agents; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Deoxyribonucleosides; Dideoxynucleosides; Fluorine; HIV-1; Humans; Lymphocytes; Molecular Structure; Pyrimidine Nucleosides; Structure-Activity Relationship; Zalcitabine | 1990 |
Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Fluorine; Gene Products, gag; HIV; HIV Antigens; HIV Core Protein p24; Humans; Macrophages; Molecular Structure; Monocytes; Pyrimidine Nucleosides; T-Lymphocytes; Tumor Cells, Cultured; Viral Core Proteins; Zalcitabine; Zidovudine | 1990 |
Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.
Topics: Animals; Antiviral Agents; Chemical Phenomena; Chemistry; Cytopathogenic Effect, Viral; Dideoxyadenosine; Dideoxynucleosides; HIV; Leukemia P388; Molecular Structure; Purine Nucleosides; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication; Zidovudine | 1990 |
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Cell Line; Dideoxynucleosides; HIV; Humans; Molecular Conformation; X-Ray Diffraction | 1990 |
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
Topics: Animals; Antiviral Agents; Cell Survival; Cells, Cultured; Chemical Phenomena; Chemistry; HIV-1; HIV-2; Mice; Molecular Conformation; Reverse Transcriptase Inhibitors; Thymine; Virus Replication | 1989 |
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
Topics: Antiviral Agents; Cell Line; Chemical Phenomena; Chemistry; Cytopathogenic Effect, Viral; Deoxyribonucleosides; HIV; Humans; Structure-Activity Relationship; T-Lymphocytes; Virus Replication | 1987 |
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
Topics: Antiviral Agents; Cell Line; HIV; Indicators and Reagents; Magnetic Resonance Spectroscopy; Moloney murine leukemia virus; Pyrimidine Nucleosides; Spectrophotometry; Structure-Activity Relationship | 1987 |
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
Topics: Algorithms; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Neural Networks, Computer; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes; Zidovudine | 1994 |
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
Topics: Antiviral Agents; Cytopathogenic Effect, Viral; Dideoxynucleosides; Drug Design; Hepatitis B virus; HIV-1; Molecular Structure; Prodrugs; Stereoisomerism; Virus Replication; Zidovudine | 1994 |
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Coumarins; HIV; HIV Reverse Transcriptase; Nucleic Acid Synthesis Inhibitors; Pyranocoumarins; RNA-Directed DNA Polymerase; Stereoisomerism | 1996 |
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Liver; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Spectrophotometry, Infrared; Structure-Activity Relationship; Uracil | 1997 |
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.
Topics: Adenosine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Cell Survival; Chlorocebus aethiops; Cyclopropanes; Guanosine; Hepatitis B virus; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV-1; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Spectrophotometry, Infrared; Vero Cells; Virus Replication | 1998 |
Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.
Topics: Acyclovir; Anti-HIV Agents; Antiviral Agents; Cell Line; Drug Evaluation, Preclinical; Guanine; Herpesvirus 1, Human; Herpesvirus 3, Human; HIV-1; Humans; Microbial Sensitivity Tests; Phosphorylation; Stereoisomerism; Structure-Activity Relationship; Thymidine Kinase; Viral Plaque Assay | 1998 |
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromones; Coumarins; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Leukocytes; Macrophages; Monocytes; Pyranocoumarins; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Structure-Activity Relationship; Virus Replication | 1998 |
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
Topics: Anti-HIV Agents; Cytidine; Enzyme Inhibitors; HIV Reverse Transcriptase; HIV-1; HIV-2; Molecular Structure; Pyridones; Structure-Activity Relationship; Uracil; Zalcitabine; Zidovudine | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Topics: Animals; Anti-HIV Agents; Cats; Cell Survival; Circular Dichroism; Citrulline; Drug Stability; HIV-1; Humans; Inhibitory Concentration 50; Oligopeptides; Peptides; Receptors, CXCR4 | 2001 |
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
Topics: Anti-HIV Agents; Calcium Signaling; Cell Division; Dipeptides; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Oligopeptides; Protein Structure, Secondary; Receptors, CXCR4; Tumor Cells, Cultured | 2002 |
New saponins from the starfish Certonardoa semiregularis.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Artemia; HeLa Cells; Humans; Korea; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Saponins; Starfish; Stereoisomerism; Steroids | 2002 |
Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
Topics: Anti-HIV Agents; Binding, Competitive; Inhibitory Concentration 50; Models, Molecular; Nucleosides; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
Topics: Animals; Antimetabolites; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Humans; Lactates; Liver Neoplasms; Mitochondria; Myocytes, Cardiac; Rats; Superoxides; Zalcitabine; Zidovudine | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
Topics: Adipocytes; Azo Compounds; Cell Survival; Cells, Cultured; Coloring Agents; DNA, Mitochondrial; Electron Transport; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glycerides; Humans; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA; Skin | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.
Topics: Animals; Drosophila melanogaster; Fluorescent Dyes; Nucleosides; Phosphotransferases (Alcohol Group Acceptor) | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
Topics: Antiviral Agents; DNA, Mitochondrial; Hep G2 Cells; Hepatitis B virus; Humans; Mitochondria; Purine Nucleosides; Reverse Transcriptase Inhibitors | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
Topics: Amines; Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication | 2012 |
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines | 2012 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Delivery Systems; Fatty Acids; HIV-1; Humans; Hydroxy Acids; Molecular Structure; Prodrugs | 2014 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Structure-Activity Relationship; Triazoles | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; HIV-1; Humans; Nucleotides; Prodrugs | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Topics: Acquired Immunodeficiency Syndrome; Base Sequence; Cell Line; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Restriction Mapping; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1992 |
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Topics: Antiviral Agents; Emtricitabine; HIV; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stereoisomerism; Zalcitabine; Zidovudine | 1992 |
Combination therapy for HIV infection: getting closer.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
A system for the high efficiency replication of HIV-1 in neural cells and its application to anti-viral evaluation.
Topics: CD4 Antigens; Cell Fusion; Cells, Cultured; HIV Core Protein p24; HIV Infections; HIV-1; Humans; In Vitro Techniques; Neurons; Recombinant Proteins; RNA, Viral; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Decreases in unintegrated HIV DNA are associated with antiretroviral therapy in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; DNA, Viral; Drug Resistance, Microbial; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Weight; Polymerase Chain Reaction; Virus Integration; Zalcitabine; Zidovudine | 1992 |
Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
Topics: Animals; Antiviral Agents; Drug Interactions; HIV; Macaca fascicularis; Male; Zalcitabine; Zidovudine | 1992 |
Trial of three drugs for HIV-infected patients.
Topics: Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides.
Topics: Adenosine Triphosphate; Animals; Carrier Proteins; Choroid Plexus; Cytarabine; Didanosine; Membrane Proteins; Nucleoside Transport Proteins; Purine Nucleosides; Pyrimidine Nucleosides; Rabbits; Sodium; Substrate Specificity; Zalcitabine; Zidovudine | 1992 |
Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine.
Topics: Acquired Immunodeficiency Syndrome; Blood Platelets; Cells, Cultured; Humans; Lamivudine; Lymphocytes; Pentosyltransferases; Phosphorylation; Pyrimidine Phosphorylases; Stereoisomerism; Thymidine Phosphorylase; Zalcitabine; Zidovudine | 1992 |
Isolation of experimental anti-AIDS glycerophospholipids by micro-preparative reversed-phase high-performance liquid chromatography.
Topics: Acquired Immunodeficiency Syndrome; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Dideoxynucleotides; Phosphatidic Acids; Spectrophotometry, Ultraviolet; Zalcitabine; Zidovudine | 1992 |
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.
Topics: Antiviral Agents; HIV-1; Humans; Lamivudine; Lymphocytes; Microbial Sensitivity Tests; Stereoisomerism; Structure-Activity Relationship; Zalcitabine; Zidovudine | 1992 |
AIDS drug made available.
Topics: Acquired Immunodeficiency Syndrome; Drug Industry; Drug Therapy, Combination; Humans; United States; Zalcitabine; Zidovudine | 1992 |
From the Food and Drug Administration.
Topics: Astemizole; Contraindications; Drug Therapy, Combination; HIV Infections; Humans; Terfenadine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1992 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |
Evaluation of multiple parameters of HIV-1 replication cycle in testing of AIDS drugs in vitro.
Topics: Antiviral Agents; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV-1; Humans; Immunologic Factors; Models, Biological; Phytohemagglutinins; RNA, Viral; Suramin; Tetradecanoylphorbol Acetate; Thymus Hormones; Virus Activation; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; HIV Infections; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1992 |
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
Topics: Drug Combinations; Drug Synergism; HIV-1; Humans; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides.
Topics: Base Sequence; Cells, Cultured; Didanosine; DNA, Viral; HIV; Humans; Lymphocyte Activation; Molecular Sequence Data; Polymerase Chain Reaction; Proviruses; T-Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Zalcitabine approved under accelerated drug review policy.
Topics: Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
Catabolic disposition of 3'-azido-2',3'-dideoxyuridine in hepatocytes with evidence of azido reduction being a general catabolic pathway of 3'-azido-2',3'-dideoxynucleosides.
Topics: Animals; Antiviral Agents; Azides; Chromatography, High Pressure Liquid; Deoxyuridine; Dideoxynucleosides; Glucuronates; Hematopoietic Stem Cells; Microsomes, Liver; NADP; Oxidation-Reduction; Rats; Rats, Inbred Strains; Ribonucleosides; Uridine Diphosphate Glucuronic Acid; Zalcitabine; Zidovudine | 1992 |
Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation.
Topics: Animals; Biological Transport, Active; Colony-Forming Units Assay; Didanosine; Dipyridamole; Dogs; Dose-Response Relationship, Drug; Erythrocytes; Female; Granulocytes; Hematopoietic Stem Cells; In Vitro Techniques; Macrophages; Zalcitabine; Zidovudine | 1992 |
Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
Topics: Cells, Cultured; Drug Interactions; Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Interferon Type I; Isoquinolines; Kinetics; Monocytes; Quinolines; Recombinant Proteins; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1992 |
FDA approves new AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Humans; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1992 |
Antiviral nucleoside diphosphate diglycerides: improved synthesis and facilitated purification.
Topics: Acyclovir; Antiviral Agents; Cytidine Diphosphate Diglycerides; Diglycerides; Lauric Acids; Myristic Acid; Myristic Acids; Nucleosides; Phosphatidic Acids; Zalcitabine; Zidovudine | 1992 |
The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Female; HIV Infections; Humans; Maternal-Fetal Exchange; Osmolar Concentration; Placenta; Pregnancy; Zalcitabine; Zidovudine | 1992 |
[New AIDS drug: dideoxycytidine (DDC)].
Topics: Acquired Immunodeficiency Syndrome; Austria; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1992 |
Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.
Topics: Animals; Antiviral Agents; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; Female; Flow Cytometry; Ganciclovir; Immunity, Cellular; Male; Nucleotides; Organ Culture Techniques; Pregnancy; Rats; Rats, Wistar; Thymus Gland; Vidarabine; Zalcitabine; Zidovudine | 1992 |
Testing an anti-HIV trio.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
AZT and ddC work better together than alone.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Drug Synergism; Humans; T-Lymphocytes; Zalcitabine; Zidovudine | 1992 |
[New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Animals; Antiviral Agents; Austria; CD4-Positive T-Lymphocytes; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1992 |
[Another AIDS drug. Azidothymidine--dideoxycytidine].
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; HIV; Humans; Leukocyte Count; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages.
Topics: Antiviral Agents; Bone Marrow; Cells, Cultured; Cytokines; Didanosine; Dideoxynucleosides; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; HIV; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Monocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Topics: Cell Death; Cells, Cultured; Didanosine; Giant Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; RNA-Directed DNA Polymerase; Tritium; Virus Replication; Zalcitabine; Zidovudine | 1992 |
[Anti-retroviral activity and molecular-biochemical action mechanism of 2',3'-dideoxynucleoside analogs and 9-(2-phosphonylmethoxyethyl) purine derivatives].
Topics: Adenine; Antiviral Agents; Humans; Phosphorylation; Pyrimidine Nucleosides; Retroviridae; Ribavirin; Structure-Activity Relationship; Zalcitabine; Zidovudine | 1991 |
The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs.
Topics: Animals; Axons; Bone Marrow; Cell Division; Cell Line, Transformed; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Peripheral Nervous System Diseases; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1991 |
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytosine; Drug Resistance, Microbial; HIV-1; Humans; Lamivudine; Nucleosides; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Therapeutic options expand, take new directions.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; United States; Zalcitabine; Zidovudine | 1991 |
AIDS. Conditional approval touted.
Topics: Acquired Immunodeficiency Syndrome; CD4 Antigens; Drug Therapy, Combination; Humans; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1991 |
Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice.
Topics: Animals; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Cells; Eating; Female; Hematologic Diseases; Hemoglobins; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred F344; Thrombocytopenia; Zalcitabine; Zidovudine | 1991 |
Better AIDS treatments.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Humans; Opportunistic Infections; Pneumonia; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1991 |
Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.
Topics: Adolescent; Antiviral Agents; Bacterial Infections; Catheterization, Central Venous; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Zalcitabine; Zidovudine | 1991 |
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine | 1991 |
Immune-associated toxicities induced by in vivo and in vitro exposure to interferon-alpha alone or in combination with nucleoside analogs.
Topics: Animals; Cells, Cultured; Female; Immune System; Interferon Type I; Lymphocyte Activation; Mice; Mice, Inbred Strains; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection.
Topics: Animals; Bone Marrow; Didanosine; Dideoxyadenosine; Female; HIV Infections; Immune System; Immunoglobulin M; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Zalcitabine; Zidovudine | 1991 |
Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Cell Survival; Dideoxynucleosides; Giant Cells; HIV; Humans; Viral Core Proteins; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Anti-HIV agents. I: Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles.
Topics: Antiviral Agents; Benzimidazoles; CD4-Positive T-Lymphocytes; Cell Line; Cytopathogenic Effect, Viral; HIV; Humans; Thiazoles; Zalcitabine; Zidovudine | 1991 |
Pharmacokinetics of anti-HIV nucleosides in microswine.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Half-Life; HIV; Male; Nucleosides; Swine; Swine, Miniature; Zalcitabine; Zidovudine | 1991 |
Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro.
Topics: Biotransformation; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Dextran Sulfate; Dextrans; Dose-Response Relationship, Drug; HIV-1; Humans; Nucleotides; Recombinant Proteins; Tumor Necrosis Factor-alpha; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Strength in numbers. Researchers begin combining compounds to fight AIDS.
Topics: Acquired Immunodeficiency Syndrome; CD4 Antigens; Didanosine; Drug Therapy, Combination; Humans; Interferons; Zalcitabine; Zidovudine | 1990 |
Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study.
Topics: Capsid; CD4 Antigens; CD4-Positive T-Lymphocytes; Cells, Cultured; HIV Antigens; HIV-1; Humans; In Vitro Techniques; Kinetics; RNA-Directed DNA Polymerase; RNA, Viral; Suramin; Virus Replication; Zalcitabine; Zidovudine | 1991 |
[Current practice and future prospects of AIDS-therapy].
Topics: Acquired Immunodeficiency Syndrome; Benzodiazepines; Drug Therapy, Combination; Humans; Imidazoles; Interferons; Thiones; Tumor Necrosis Factor-alpha; Zalcitabine; Zidovudine | 1990 |
Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics.
Topics: Antiviral Agents; Dideoxynucleosides; DNA Replication; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; In Vitro Techniques; Interferon Type I; Stavudine; Vidarabine; Vidarabine Phosphate; Virus Replication; Zalcitabine; Zidovudine | 1991 |
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Didanosine; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Thymine; Zalcitabine; Zidovudine | 1991 |
[Combination therapies with anti-retroviral agents in HIV and AIDS infections].
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Zalcitabine; Zidovudine | 1991 |
Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; HIV Infections; Mice; Mice, Inbred C57BL; Zalcitabine; Zidovudine | 1991 |
[AIDS: initial results of combination therapy. AIDS and ARC--alternating or intermittent medication].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; CD4 Antigens; Combined Modality Therapy; HIV; Humans; Immunotherapy, Adoptive; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.
Topics: Antiviral Agents; Cell Line; Cytarabine; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; HIV; Humans; Lymphocyte Activation; Nucleosides; Stavudine; T-Lymphocytes; Zalcitabine; Zidovudine | 1991 |
Synthesis and biological evaluation of dinucleoside methylphosphonates of 3'-azido-3'-deoxythymidine and 2', 3'-dideoxycytidine.
Topics: Animals; Antineoplastic Agents; Deoxycytosine Nucleotides; Drug Evaluation, Preclinical; HIV; Hydrolysis; Mice; Mice, Inbred C3H; Moloney murine sarcoma virus; Thymine Nucleotides; Tumor Cells, Cultured; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Humans; Liver; Rats; Zalcitabine; Zidovudine | 1990 |
Drugs for HIV infection.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Cross-resistance to anti-HIV nucleoside analogs in multidrug-resistant human cells.
Topics: Biological Transport; Cell Division; Cell Line; Drug Resistance; Humans; In Vitro Techniques; Zalcitabine; Zidovudine | 1990 |
2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.
Topics: Cell Division; Cell Line; Cell Survival; Deoxycytidine Kinase; Deoxycytosine Nucleotides; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Interactions; Humans; Phosphorylation; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine | 1990 |
Clinical trials of combination therapies for HIV infection. Discussion.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Clinical trials of combination therapies for HIV infection. Rationale for development of multidrug therapy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1990 |
Strategies for the combination therapy of HIV infection.
Topics: Acyclovir; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Virus Replication; Zalcitabine; Zidovudine | 1990 |
3'-Azido-3'-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells.
Topics: Anemia; Butyrates; Butyric Acid; Dose-Response Relationship, Drug; Globins; Hemoglobins; Humans; Leukemia, Erythroblastic, Acute; Protein Biosynthesis; Transcription, Genetic; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1990 |
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cell Line, Transformed; Colorimetry; Cytopathogenic Effect, Viral; Dextran Sulfate; Dextrans; Dideoxynucleosides; Drug Evaluation, Preclinical; Heparin; HIV; Humans; Tetrazolium Salts; Thiazoles; Zalcitabine; Zidovudine | 1988 |
Antiviral effects of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and 2',3'-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro.
Topics: Animals; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Dideoxyadenosine; Dideoxynucleosides; Humans; Macaca mulatta; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Zalcitabine; Zidovudine | 1988 |
An in vitro system for screening anti-hepatitis B virus drugs.
Topics: Acyclovir; Adenine; Antiviral Agents; Blotting, Southern; Carcinoma, Hepatocellular; Cytarabine; Dideoxyadenosine; Dideoxynucleosides; DNA Replication; DNA, Viral; Hepatitis B virus; Humans; Interferons; Liver Neoplasms; Tumor Cells, Cultured; Vidarabine; Virus Replication; Zalcitabine; Zidovudine | 1989 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Foscarnet; HeLa Cells; HIV; HIV Core Protein p24; Humans; Microbial Sensitivity Tests; Phosphonoacetic Acid; Retroviridae Proteins; Reverse Transcriptase Inhibitors; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Inhibitory effect of azidothymidine, 2'-3'-dideoxyadenosine, and 2'-3'-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Bone Marrow; Colony-Forming Units Assay; Deoxyribonucleosides; Dideoxyadenosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Growth Inhibitors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Zalcitabine; Zidovudine | 1989 |
Testing of nucleoside analogues in cats infected with feline leukemia virus: a model.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antibodies, Viral; Antiviral Agents; Cats; Cell Line; Didanosine; Dideoxyadenosine; Dideoxynucleosides; Disease Models, Animal; Drug Evaluation, Preclinical; Immunologic Deficiency Syndromes; Leukemia Virus, Feline; Leukemia, Experimental; Nucleosides; Specific Pathogen-Free Organisms; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.
Topics: Antiviral Agents; Biological Transport; Bone Marrow; Bone Marrow Cells; Cell Survival; Dideoxynucleosides; Dipyridamole; Drug Synergism; HIV; Humans; In Vitro Techniques; Interferon Type I; Macrophages; Monocytes; Virus Replication; Zalcitabine; Zidovudine | 1989 |
In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus.
Topics: Antiviral Agents; Bone Marrow Diseases; Colony-Forming Units Assay; Dideoxynucleosides; HIV; Humans; Nucleosides; Zalcitabine; Zidovudine | 1989 |
Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
Topics: Antiviral Agents; Cells, Cultured; Dideoxynucleosides; DNA, Viral; HIV; Humans; Time Factors; Virus Replication; Zalcitabine; Zidovudine | 1989 |
[AIDS: small, life-prolonging steps. Antiviral therapy is more efficient--a decrease in side effects].
Topics: Acquired Immunodeficiency Syndrome; HIV; Humans; Zalcitabine; Zidovudine | 1989 |
A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antigen-Antibody Reactions; Antiviral Agents; Bone Marrow; Dideoxyadenosine; Female; Hematopoiesis; HIV; Immunity, Cellular; Macrophages; Mice; Mice, Inbred C57BL; Spleen; Stem Cells; T-Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1989 |
The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.
Topics: Antiviral Agents; Cell Division; Cell Line; Dideoxynucleosides; HIV; Humans; Virus Replication; Zalcitabine; Zidovudine | 1989 |
AZT/ddC combination may benefit AIDS sufferers.
Topics: Acquired Immunodeficiency Syndrome; Drug Combinations; Humans; Zalcitabine; Zidovudine | 1989 |
Several new AIDS drugs being tested.
Topics: 1-Deoxynojirimycin; Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; CD4 Antigens; Drug Therapy, Combination; Glucosamine; Humans; Interferon Type I; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1989 |
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Line; Cytopathogenic Effect, Viral; Dose-Response Relationship, Drug; HIV Antigens; HIV-1; HIV-2; Lymphocytes; Macrophages; Thymine; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Anti-HIV drugs: comparative toxicities in murine fetal liver and bone marrow erythroid progenitor cells.
Topics: Animals; Antiviral Agents; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Dideoxynucleosides; Fetus; Hematopoietic Stem Cells; HIV; Liver; Mice; Ribavirin; Zalcitabine; Zidovudine | 1989 |
Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus.
Topics: Antigens, Viral; Antiviral Agents; Cell Line; Cell Survival; Cytopathogenic Effect, Viral; Deoxycytidine; Flow Cytometry; Fluorescent Antibody Technique; HIV; Humans; Thymidine; Zalcitabine; Zidovudine | 1987 |
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages.
Topics: Adenosine Kinase; Cell Line; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dideoxyadenosine; HIV; Humans; Macrophages; Phosphorylation; T-Lymphocytes; Thymidine; Thymidine Kinase; Uridine Kinase; Virus Replication; Zalcitabine; Zidovudine | 1987 |
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.
Topics: Animals; Antiviral Agents; Cell Line; Deoxycytidine; HIV; Humans; Mice; Mice, Inbred C3H; Moloney murine sarcoma virus; Retroviridae; Thymidine; Zalcitabine; Zidovudine | 1988 |
Therapy for neurological involvement in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Blood-Brain Barrier; Central Nervous System Diseases; Deoxycytidine; Humans; Immunotherapy; Molecular Biology; Retroviridae; Thymidine; Zalcitabine; Zidovudine | 1988 |
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.
Topics: Cytopathogenic Effect, Viral; Deoxyadenosines; Deoxycytidine; Dideoxyadenosine; HIV; In Vitro Techniques; Nucleosides; Retroviridae; T-Lymphocytes, Helper-Inducer; Thymidine; Viral Proteins; Virus Replication; Zalcitabine; Zidovudine | 1988 |
Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; Drug Synergism; HIV; Humans; Interferon Type I; Leukocytes; Recombinant Proteins; Thymidine; Virus Replication; Zalcitabine; Zidovudine | 1988 |
Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier.
Topics: Animals; Antiviral Agents; Blood-Brain Barrier; Deoxyadenosines; Deoxycytidine; Dideoxyadenosine; Liver; Male; Rats; Rats, Inbred Strains; Thymidine; Zalcitabine; Zidovudine | 1988 |
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Deoxycytidine Kinase; Dideoxyadenosine; Dideoxynucleosides; HIV; Humans; In Vitro Techniques; Macrophages; Monocytes; Phosphorylation; Thymidine Kinase; Time Factors; Virus Replication; Zalcitabine; Zidovudine | 1988 |
Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytopathogenic Effect, Viral; Dideoxynucleosides; HIV; Molecular Structure; Structure-Activity Relationship; Virus Replication; Zalcitabine; Zidovudine | 1988 |
Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives.
Topics: Acquired Immunodeficiency Syndrome; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Depression, Chemical; Dideoxynucleosides; Erythropoiesis; Humans; Zalcitabine; Zidovudine | 1988 |
[HIV infection. Zidovudine and 2',3'-dideoxycytidine in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1988 |
High-performance liquid chromatographic determination of 2',3'-dideoxycytidine and 3'-azido-3'-deoxythymidine in plasma using a column-switching technique.
Topics: Animals; Cats; Chromatography, High Pressure Liquid; Dideoxynucleosides; Reference Standards; Zalcitabine; Zidovudine | 1988 |
Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Biological Availability; Chromatography, High Pressure Liquid; Dideoxynucleosides; Humans; Injections, Intravenous; Zalcitabine; Zidovudine | 1988 |
Sensitization of X-irradiated Chinese hamster V79 cells by derivatives of pyrimidine nucleosides.
Topics: Animals; Antiviral Agents; Cell Count; Cell Line; Cell Survival; Dideoxynucleosides; Pyrimidine Nucleosides; Radiation-Sensitizing Agents; Stavudine; Zalcitabine; Zidovudine | 1988 |
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; HIV; Humans; Male; Middle Aged; Thymidine; Zalcitabine; Zidovudine | 1988 |
Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro.
Topics: Antiviral Agents; Deoxycytidine; Fluorescence; HIV; Humans; In Vitro Techniques; Monocytes; Thymidine; Zalcitabine; Zidovudine | 1987 |
Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.
Topics: Deltaretrovirus; Deoxycytidine; DNA, Viral; Humans; Lymphocyte Activation; T-Lymphocytes, Helper-Inducer; Tetanus Toxoid; Thymidine; Virus Replication; Zalcitabine; Zidovudine | 1987 |
Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus.
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Dideoxynucleosides; HIV; Humans; Stavudine; Thymidine; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1987 |
[Antiretroviral treatment against HIV].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
HIV-1, the brain, and combination therapy.
Topics: Adult; AIDS Dementia Complex; Antiviral Agents; Child; Didanosine; Drug Combinations; HIV-1; Humans; Lamivudine; Neuroprotective Agents; Stavudine; Zalcitabine; Zidovudine | 1995 |
A quarter-century of antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Didanosine; Female; HIV Seropositivity; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocytes; Male; Phytohemagglutinins; Zalcitabine; Zidovudine | 1995 |
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunocompromised Host; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cells, Cultured; Dideoxynucleosides; Drug Interactions; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; Models, Biological; Reproducibility of Results; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1993 |
[AIDS therapy with reverse transcriptase inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1993 |
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Leukocytes, Mononuclear; Piperazines; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1994 |
Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides.
Topics: Animals; Antiviral Agents; Cattle; Cell Line; Cell Survival; Colony-Forming Units Assay; Deoxycytidine Kinase; Drug Resistance, Microbial; Hepatitis B virus; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thymus Gland; Viruses; Zalcitabine; Zidovudine | 1994 |
[Anti-HIV-therapy. Monotherapy with drugs delaying the course of the disease has limited effect].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Palliative Care; Zalcitabine; Zidovudine | 1994 |
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
Topics: Base Sequence; Cells, Cultured; Drug Resistance, Microbial; Emtricitabine; HeLa Cells; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1994 |
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Fetal Blood; HIV Core Protein p24; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Microbial Sensitivity Tests; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cloning, Molecular; DNA, Viral; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Nevirapine; Point Mutation; Polymerase Chain Reaction; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Virus Cultivation; Zalcitabine; Zidovudine | 1994 |
Fighting all the time.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1995 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |
A screen in Escherichia coli for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase.
Topics: Antiviral Agents; Cloning, Molecular; Cytarabine; DNA Polymerase I; Drug Evaluation, Preclinical; Escherichia coli; Gene Expression; HIV; Kinetics; Phosphorylation; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Simplexvirus; Thymidine Kinase; Zalcitabine; Zidovudine | 1995 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Combination superior to zidovudine in Delta trial.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
AZT combination trial shows positive results.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Confirmation for combination AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Removal of anti-human immunodeficiency virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'-->5' exonuclease.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytosol; Dideoxynucleosides; DNA, Single-Stranded; Exonucleases; HIV-1; Humans; Molecular Sequence Data; Phosphates; Stavudine; Stereoisomerism; Substrate Specificity; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Study shows two drugs are best for HIV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
Topics: Antiviral Agents; Base Sequence; Cell Fusion; Cell Line; Coculture Techniques; DNA Mutational Analysis; Drug Resistance, Multiple; Genes, pol; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Monocytes; Polymerase Chain Reaction; Recombination, Genetic; T-Lymphocytes; Virus Cultivation; Zalcitabine; Zidovudine | 1995 |
Development of a yeast retrotransposon-based system useful for screening of potentially active anti-retroviral compounds.
Topics: Antiviral Agents; Drug Evaluation, Preclinical; Genetic Vectors; Retroelements; Retroviridae; Saccharomyces cerevisiae; Zalcitabine; Zidovudine | 1995 |
Down-regulation of interleukin-2 receptor gene activation and protein expression by dideoxynucleoside analogs.
Topics: Antigens, Surface; Base Sequence; Cell Division; Dideoxynucleosides; Down-Regulation; Gene Expression; Gene Expression Regulation; Humans; Interleukin-2; Leukocytes, Mononuclear; Lymphocyte Activation; Molecular Sequence Data; Phytohemagglutinins; Protein Biosynthesis; Proteins; Receptors, Interleukin-2; Transcriptional Activation; Zalcitabine; Zidovudine | 1995 |
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Cardiomyopathies; CD4 Lymphocyte Count; Child, Preschool; Didanosine; Dose-Response Relationship, Drug; Echocardiography; Female; Heart; HIV; Humans; Infant; Infant, Newborn; Male; Medical Records; Retrospective Studies; Severity of Illness Index; Zalcitabine; Zidovudine | 1995 |
More HIV patients may benefit from zalcitabine now.
Topics: Drug Therapy, Combination; HIV Infections; Humans; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Topics: Adenosine Kinase; Cells, Cultured; Didanosine; DNA Replication; Drug Synergism; HIV-1; Humans; Hydroxyurea; Phosphorylation; Proviruses; Uridine Kinase; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Topics: Amino Acid Sequence; Antiviral Agents; Cell Line; Conserved Sequence; Deoxycytidine; Drug Resistance, Microbial; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Structure-Activity Relationship; T-Lymphocytes; Thionucleosides; Zalcitabine; Zidovudine | 1993 |
Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.
Topics: Animals; Female; HIV; Lymphoid Tissue; Mice; Mice, Inbred BALB C; Phospholipids; Prodrugs; Rauscher Virus; Zalcitabine; Zidovudine | 1994 |
Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
Topics: Antiviral Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Efficiency; Evaluation Studies as Topic; Genes, pol; Genotype; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Proviruses; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Templates, Genetic; Virion; Zalcitabine; Zidovudine | 1994 |
Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication.
Topics: Antibodies, Monoclonal; Cells, Cultured; Cytopathogenic Effect, Viral; Didanosine; HIV Core Protein p24; HIV-1; Humans; Interleukin-12; Interleukin-4; Interleukins; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophages; Monocytes; Muromonab-CD3; Phytohemagglutinins; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1995 |
[AIDS: combination drug partner for AZT. HIV infection--new nucleoside analog].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1994 |
Induction of resistance to 1-beta-D-arabinofuranosylcytosine in human H9 cell line by simian immunodeficiency virus.
Topics: Cell Division; Cell Line; Cell Survival; Cytarabine; Cytidine Deaminase; Drug Resistance; Fluorouracil; Humans; Leukemia-Lymphoma, Adult T-Cell; Mercaptopurine; Simian Immunodeficiency Virus; Tetrahydrouridine; Tumor Cells, Cultured; Vidarabine; Zalcitabine; Zidovudine | 1995 |
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
Topics: Analysis of Variance; B-Lymphocytes; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Phosphorylation; Phytohemagglutinins; Thymidine; Zalcitabine; Zidovudine | 1994 |
AIDS mood upbeat--for a change.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; Gene Products, nef; Herpesviridae; HIV; Humans; Lamivudine; nef Gene Products, Human Immunodeficiency Virus; Sarcoma, Kaposi; Simian Immunodeficiency Virus; Virus Replication; Zalcitabine; Zidovudine | 1995 |
3"-Azido-3'-deoxythymidine and 2',3'-dideoxycytidine do not inhibit gene-specific DNA repair in hamster cells.
Topics: Animals; CHO Cells; Clone Cells; Cricetinae; DNA; DNA Damage; DNA Repair; DNA Replication; Genes; Kinetics; Time Factors; Ultraviolet Rays; Zalcitabine; Zidovudine | 1995 |
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
Topics: Didanosine; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Zalcitabine; Zidovudine | 1993 |
Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection.
Topics: AIDS-Related Opportunistic Infections; Blood Component Transfusion; Blood Group Antigens; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cell Count; Cytomegalovirus Infections; Didanosine; Erythrocyte Transfusion; Female; HIV-1; Humans; Isoantibodies; Male; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Risk Factors; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy in HIV-infected adults. Which regimens are recommended?
Topics: Adult; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1994 |
Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Topics: Cell Division; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV-1; Humans; Interphase; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Lower socioeconomic status and shorter survival following HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Health Services; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Income; Male; Pneumonia, Pneumocystis; Regression Analysis; Socioeconomic Factors; Survival Rate; Zalcitabine; Zidovudine | 1994 |
[HIV infection--current possibilities in antiviral therapy].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Pancreatitis; Zalcitabine; Zidovudine | 1994 |
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Dideoxynucleosides; Drug Synergism; HIV-1; Humans; Hydroxyurea; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; Humans; Hydroxyurea; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma.
Topics: Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Cytosine; Dideoxynucleotides; DNA Polymerase I; DNA Polymerase III; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Organophosphorus Compounds; Thymine Nucleotides; Zalcitabine; Zidovudine | 1994 |
Potentiation of 2',3'-dideoxycytidine (ddC) by hydroxyurea and thymidine on the Moloney murine leukemia virus (MoMLV) early replicative steps.
Topics: 3T3 Cells; Animals; Drug Synergism; Hydroxyurea; Mice; Moloney murine leukemia virus; Thymidine; Transcription, Genetic; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cell Line; Cloning, Molecular; Didanosine; Drug Interactions; Drug Resistance, Microbial; HIV-1; Humans; Interferon-alpha; Neutralization Tests; Phenotype; Serial Passage; Stavudine; Zalcitabine; Zidovudine | 1994 |
Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Humans; Membrane Proteins; Molecular Sequence Data; Nucleoside Transport Proteins; Nucleosides; Oocytes; Protein Conformation; Rats; Uridine; Xenopus; Zalcitabine; Zidovudine | 1994 |
[The anti-viral agents used in the treatment of AIDS].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Zalcitabine; Zidovudine | 1994 |
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine | 1994 |
In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
Topics: Antiviral Agents; Azepines; Cells, Cultured; Didanosine; Giant Cells; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Species Specificity; Zalcitabine; Zidovudine | 1994 |
What to do when zidovudine fails.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
Topics: Adult; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Needlestick Injuries; Recombinant Proteins; Zalcitabine; Zidovudine | 1994 |
Intermittent therapy.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Pharmacotherapy of HIV. APhA Editorial Board on Pharmaceutical Care for Patients with HIV Infection.
Topics: Adult; CD4 Antigens; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Pharmaceutical Services; Zalcitabine; Zidovudine | 1994 |
Comparative embryonic cytotoxicity of antiretroviral nucleosides.
Topics: Animals; Antiviral Agents; Culture Techniques; Didanosine; Embryo, Mammalian; HIV; Mice; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1994 |
The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Male; Muscular Diseases; Zalcitabine; Zidovudine | 1994 |
Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
Topics: Cell Line; Culture Media; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Microscopy, Electron; Time Factors; Zalcitabine; Zidovudine | 1993 |
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; Drug Resistance, Microbial; HIV Seropositivity; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Time Factors; Zalcitabine; Zidovudine | 1994 |
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Consensus Sequence; Didanosine; Genes, pol; Genotype; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Point Mutation; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Time Factors; Viral Plaque Assay; Zalcitabine; Zidovudine | 1993 |
Regulation of megakaryocyte colony forming cell numbers and ploidy by dideoxynucleosides in immunodeficient mice.
Topics: Animals; Bone Marrow; Colony-Forming Units Assay; Didanosine; Female; Hematocrit; Hematopoietic Stem Cells; Leukemia Virus, Murine; Megakaryocytes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Platelet Count; Ploidies; Spleen; Zalcitabine; Zidovudine | 1993 |
[Treatment by antiviral drugs of HIV-infected patients].
Topics: Acyclovir; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interferon-alpha; Zalcitabine; Zidovudine | 1993 |
Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum.
Topics: Antiviral Agents; Biological Availability; Half-Life; Humans; Male; Quality Control; Radioimmunoassay; Sensitivity and Specificity; Zalcitabine; Zidovudine | 1994 |
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Didanosine; Dose-Response Relationship, Drug; Genetic Variation; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid; Zalcitabine; Zidovudine | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Dapsone; Didanosine; Drug Combinations; Follow-Up Studies; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; San Francisco; Sulfamethizole; Trimethoprim; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy.
Topics: Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1993 |
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Topics: 5'-Nucleotidase; Acquired Immunodeficiency Syndrome; Adenosine Kinase; AIDS-Related Complex; Chromatography, High Pressure Liquid; Deoxycytidine Kinase; Deoxyribonucleotides; Didanosine; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Monocytes; Phosphorylation; Thymidine Kinase; Uridine Kinase; Zalcitabine; Zidovudine | 1993 |
Somber news from the AIDS front.
Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Male; Sexually Transmitted Diseases; Zalcitabine; Zidovudine | 1993 |
Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
Topics: 1-Deoxynojirimycin; Antiviral Agents; CD4 Antigens; Cell Line; Didanosine; Drug Interactions; HIV Envelope Protein gp120; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
Topics: Antiviral Agents; B-Lymphocytes; CD3 Complex; Cytokines; Female; HIV Infections; HIV-1; Humans; Immunoglobulins; Lamivudine; Lymphocyte Activation; Male; Phytohemagglutinins; T-Lymphocytes; Zalcitabine; Zidovudine | 1993 |
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Child; Child, Preschool; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV-1; Humans; Infant; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Time Factors; Zalcitabine; Zidovudine | 1993 |
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Brain; Cells, Cultured; DNA, Viral; Fetus; HIV Core Protein p24; HIV-1; Humans; Lamivudine; Macrophages; RNA, Messenger; Stereoisomerism; Time Factors; Virus Replication; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Didanosine; HIV Infections; Humans; Immunoglobulins, Intravenous; Infant; Zalcitabine; Zidovudine | 1993 |
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Complex; Antigens, CD; Biomarkers; Body Weight; CD4 Antigens; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Core Protein p24; Humans; Male; Middle Aged; Pilot Projects; T-Lymphocyte Subsets; Time Factors; Zalcitabine; Zidovudine | 1993 |
Preliminary study analysis suggests similar efficacy for didanosine and zalcitabine.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1993 |
[Is early combined AIDS treatment an advantage? Nucleoside analogs--study will bring enlightenment].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Humans; Leukocyte Count; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1993 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation.
Topics: Administration, Cutaneous; Animals; Anti-Infective Agents, Local; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Enzyme Inhibitors; Female; Half-Life; HIV-1; In Vitro Techniques; Rats; Rats, Nude; Skin Absorption; Zalcitabine; Zidovudine | 1995 |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Topics: Antiviral Agents; Base Sequence; Cells, Cultured; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Conformation; Nucleosides; Nucleotides; Phytohemagglutinins; RNA, Viral; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 1996 |
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Humans; Interleukin-2; Lamivudine; Lymphocyte Activation; Zalcitabine; Zidovudine | 1994 |
A new HIV/AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Zalcitabine; Zidovudine | 1996 |
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytomegalovirus; Drug Interactions; Foscarnet; Ganciclovir; HIV-1; Humans; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; RNA, Viral; Thionucleotides; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Increased zidovudine prescribing associated with lamivudine availability.
Topics: Antiviral Agents; British Columbia; Drug Utilization; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Managing HIV disease after Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis.
Topics: Chemical and Drug Induced Liver Injury; Erythema; Female; HIV Infections; Humans; Middle Aged; Zalcitabine; Zidovudine | 1996 |
The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cats; Cell Line; Didanosine; Dose-Response Relationship, Drug; Gene Frequency; Immunodeficiency Virus, Feline; Kidney; Mutation; Virus Cultivation; Zalcitabine; Zidovudine | 1996 |
Lamivudine as adjunct therapy in HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.
Topics: Animals; Antiviral Agents; Cells, Cultured; Drug Evaluation, Preclinical; HIV; HIV Core Protein p24; Humans; Mice; Mice, SCID; RNA-Directed DNA Polymerase; Virus Cultivation; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina.
Topics: Amniotic Fluid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Antiviral Agents; Cattle; Cross-Over Studies; Drug Interactions; Female; Fetal Blood; Macaca nemestrina; Placenta; Pregnancy; Random Allocation; Zalcitabine; Zidovudine | 1996 |
Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts.
Topics: Antiviral Agents; Cells, Cultured; Dideoxynucleosides; DNA, Mitochondrial; Humans; Kearns-Sayre Syndrome; Polymerase Chain Reaction; Sequence Deletion; Zalcitabine; Zidovudine | 1996 |
Monoblastic leukemia in an HIV-infected patient: absence of viral expression in RNA blasts.
Topics: Adult; Bone Marrow; DNA, Viral; Fatal Outcome; Foot Diseases; Gene Expression; HIV Infections; HIV-1; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Male; Neoplastic Stem Cells; RNA, Viral; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1996 |
Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Drug Utilization; Follow-Up Studies; Hemoglobins; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
New nucleoside analogue, lamivudine, released for HIV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Infection and cellular activation by human T-cell leukemia viruses, types I and II.
Topics: Antigens, CD; Antiviral Agents; B-Lymphocytes; Cell Division; Cell Line; env Gene Products, Human Immunodeficiency Virus; Gene Products, env; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Retroviridae Proteins, Oncogenic; T-Lymphocytes; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1996 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation.
Topics: Animals; Antiviral Agents; Didanosine; Drug Delivery Systems; Female; Rats; Skin; Zalcitabine; Zidovudine | 1996 |
Adverse events from drug therapy for human immunodeficiency virus disease.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Female; HIV Infections; Humans; Male; Pneumonia, Pneumocystis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health; Zalcitabine; Zidovudine | 1996 |
New guidelines set for occupational HIV exposure.
Topics: Accidents, Occupational; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Practice Guidelines as Topic; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral monotherapy with nucleoside analogues].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
[Resistance and combined use of anti-HIV drugs].
Topics: Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Mutation; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
Topics: Animals; Antiviral Agents; Biological Transport; Carrier Proteins; Dose-Response Relationship, Drug; Female; Intestinal Absorption; Membrane Proteins; Nucleoside Transport Proteins; Probenecid; Rats; Recombinant Proteins; Uridine; Xenopus laevis; Zalcitabine; Zidovudine | 1996 |
HIV's Achilles' heel. Drugs and education are starting to slow the AIDS virus.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; Health Education; Humans; Indinavir; Lamivudine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Topics: Antiviral Agents; Codon; Drug Therapy, Combination; Genetic Variation; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1996 |
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiality; Conflict of Interest; Didanosine; Drug Evaluation; Federal Government; HIV Infections; Humans; National Institutes of Health (U.S.); Organizational Objectives; Professional Staff Committees; Pyrimethamine; Reverse Transcriptase Inhibitors; Risk Assessment; Toxoplasmosis, Cerebral; Treatment Outcome; United States; Zalcitabine; Zidovudine | 1995 |
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine | 1996 |
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation.
Topics: Antiviral Agents; Humans; Lamivudine; Phosphorylation; Zalcitabine; Zidovudine | 1996 |
Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell Division; Didanosine; HIV Infections; HL-60 Cells; Humans; Zalcitabine; Zidovudine | 1996 |
Combination drug treatment benefits patients with HIV.
Topics: Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices].
Topics: Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Drug Utilization; France; HIV Infections; Hospital Information Systems; Hospital Records; Humans; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Therapy of HIV infections: problems and prospects.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Stavudine; Urban Health; Zalcitabine; Zidovudine | 1996 |
Therapy for human immunodeficiency virus infection -- what have we learned?
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.
Topics: Antiviral Agents; Cells, Cultured; Colony-Forming Units Assay; Dideoxynucleosides; Hematopoietic Stem Cells; Humans; Linear Models; Zalcitabine; Zidovudine | 1996 |
Effect of antiviral treatments on the bone marrow in murine aids.
Topics: Animals; Antiviral Agents; Bone Marrow; Dideoxynucleotides; Gene Products, gag; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Thymine Nucleotides; Zalcitabine; Zidovudine | 1995 |
Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; Cats; Cell Line; Didanosine; Drug Resistance, Microbial; Immunodeficiency Virus, Feline; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
[What should be done after needlestick injuries with possible HIV exposure?].
Topics: Antiviral Agents; Drug Therapy, Combination; First Aid; HIV Infections; Humans; Needlestick Injuries; Risk Factors; Zalcitabine; Zidovudine | 1996 |
Inhibition of the in vitro infectivity and cytopathic effect of human foamy virus by dideoxynucleosides.
Topics: Blotting, Southern; Cytopathogenic Effect, Viral; Didanosine; Dideoxynucleosides; DNA, Viral; Humans; Microscopy, Electron; Spumavirus; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1996 |
Occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type 1.
Topics: Antiviral Agents; HIV Infections; HIV-1; Humans; Lymphoma; Zalcitabine; Zidovudine | 1996 |
[HIV: to administer protease inhibitors early].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Time Factors; Zalcitabine; Zidovudine | 1996 |
Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Topics: Anti-HIV Agents; Apoptosis; Cell Line; Didanosine; DNA Fragmentation; Down-Regulation; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine | 1997 |
The Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1997 |
Renal involvement in the diffuse infiltrative CD8 lymphocytosis syndrome.
Topics: Adult; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infections; Humans; Kidney Diseases; Lymphocytosis; Male; Prednisone; Zalcitabine; Zidovudine | 1997 |
Treatment of late-state HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alcohol Drinking; Amylases; Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; Didanosine; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Seropositivity; Humans; Liver Function Tests; Male; Marijuana Smoking; Middle Aged; Pancreatitis, Alcoholic; Zalcitabine; Zidovudine | 1997 |
Effects of ddC and AZT on locomotion and acoustic startle. I: Acute effects in female rats.
Topics: Acoustic Stimulation; Animals; Anti-HIV Agents; Female; Motor Activity; Rats; Rats, Sprague-Dawley; Reflex, Startle; Zalcitabine; Zidovudine | 1997 |
Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells.
Topics: Animals; Didanosine; Dideoxynucleosides; DNA Replication; DNA, Mitochondrial; Nerve Growth Factors; Neurites; PC12 Cells; Phosphorylation; Rats; Stavudine; Zalcitabine; Zidovudine | 1997 |
In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination.
Topics: Bone Marrow Cells; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Drug Synergism; Erythropoiesis; Hematopoiesis; Hematopoietic Stem Cells; Humans; Zalcitabine; Zidovudine | 1997 |
In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.
Topics: Anti-HIV Agents; Biotransformation; Drug Evaluation, Preclinical; Drug Interactions; Humans; Lamivudine; Phosphorylation; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
[Therapeutic strategies against HIV: status in 1994 and future prospectives].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Forecasting; HIV Infections; Humans; Male; Zalcitabine; Zidovudine | 1994 |
Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Saquinavir; Thrombocytopenia; Zalcitabine; Zidovudine | 1997 |
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
Topics: Anti-HIV Agents; Biopsy; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport Complex II; Electron Transport Complex IV; Humans; Kinetics; Lactates; Lipid Metabolism; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; NAD(P)H Dehydrogenase (Quinone); Nucleic Acid Synthesis Inhibitors; Oxidoreductases; Succinate Dehydrogenase; Zalcitabine; Zidovudine | 1997 |
Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Topics: Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Longitudinal Studies; RNA, Viral; Stavudine; Viral Load; Viremia; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biopterins; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Core Protein p24; HIV-1; Humans; Infant; Longitudinal Studies; Male; Neopterin; Polymerase Chain Reaction; Retrospective Studies; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
[Anti-retrovirals].
Topics: Anti-HIV Agents; Didanosine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1997 |
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes.
Topics: Acyclovir; Cell Line; Dose-Response Relationship, Drug; Ganciclovir; Genetic Therapy; Growth Inhibitors; Herpesvirus 1, Human; HIV-1; Humans; Hydroxyurea; Nucleosides; Stavudine; Substrate Specificity; T-Lymphocytes; Thymidine Kinase; Zalcitabine; Zidovudine | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Lymphocyte Activation; Lymphocytes; Mitogens; Models, Chemical; Monocytes; Phosphorylation; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Combined Modality Therapy; DNA, Recombinant; Dose-Response Relationship, Drug; Gene Products, gag; Gene Products, rev; Genetic Therapy; Genetic Vectors; Genome, Viral; HIV Core Protein p24; HIV-1; Humans; Indinavir; rev Gene Products, Human Immunodeficiency Virus; RNA, Antisense; T-Lymphocytes; Zalcitabine; Zidovudine | 1997 |
[Initial administration of a protease inhibitor delays the progression of AIDS by half time].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Disease Progression; HIV Infections; HIV Protease Inhibitors; Humans; Time Factors; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; HIV Infections; Humans; Research Design; Saquinavir; Survival Analysis; Zalcitabine; Zidovudine | 1997 |
Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs.
Topics: Antimetabolites; Apoptosis; Cell Count; Cell Cycle; Cell Line; Dideoxynucleosides; DNA Fragmentation; Flow Cytometry; Humans; Neutrophils; Phytohemagglutinins; T-Lymphocytes; Zalcitabine; Zidovudine | 1997 |
Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Herpesvirus 8, Human; Humans; Leukocytes, Mononuclear; Male; Sarcoma, Kaposi; Viral Load; Zalcitabine; Zidovudine | 1998 |
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Topics: Animals; Anti-HIV Agents; Cell Line, Transformed; COS Cells; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Oligopeptides; Polymerase Chain Reaction; Recombination, Genetic; Reverse Transcriptase Inhibitors; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Complete remission of a primary effusion lymphoma with antiretroviral therapy.
Topics: Aged; Anti-HIV Agents; Exudates and Transudates; Homosexuality, Male; Humans; Lymphoma, AIDS-Related; Male; Remission Induction; Zalcitabine; Zidovudine | 1998 |
Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.
Topics: Anti-HIV Agents; Cohort Studies; Cost Savings; Costs and Cost Analysis; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Prospective Studies; Zalcitabine; Zidovudine | 1998 |
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; COS Cells; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Evolution, Molecular; Genes, pol; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Mutation; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Profound anemia in a newborn infant of a mother receiving antiretroviral therapy.
Topics: Adult; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Leukocyte Count; Male; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zalcitabine; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
A mixed model for repeated dilution assays.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Viral Load; Zalcitabine; Zidovudine | 1998 |
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Topics: Anti-HIV Agents; Cell Line; Deamination; Deoxycytidine Kinase; Didanosine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; DNA, Viral; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Phosphorylation; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Brain Diseases; Didanosine; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Retrospective Studies; Risk; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Analysis of antiretroviral nucleosides by electrospray ionization mass spectrometry and collision induced dissociation.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Gas Chromatography-Mass Spectrometry; Lamivudine; Models, Chemical; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Secondary Ion; Zalcitabine; Zidovudine | 1998 |
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Mutation; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1998 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.
Topics: Antiviral Agents; Cytotoxicity, Immunologic; Cytotoxins; Drug Combinations; Humans; Intestines; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Phytohemagglutinins; RNA, Messenger; Saquinavir; Zalcitabine; Zidovudine | 1998 |
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cells, Cultured; Didanosine; Drug Resistance, Multiple; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Italy; Occupational Exposure; Registries; Retrospective Studies; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection].
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Hemophilia A; HIV Infections; Humans; Indinavir; Lipomatosis, Multiple Symmetrical; Male; Zalcitabine; Zidovudine | 1998 |
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Enzyme Induction; HIV Infections; HIV-1; Humans; Lymphoid Tissue; Reverse Transcriptase Inhibitors; Telomerase; Telomere; Up-Regulation; Zalcitabine; Zidovudine | 1999 |
Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cross-Cultural Comparison; Drug Costs; Europe; Follow-Up Studies; Humans; Zalcitabine; Zidovudine | 1994 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
PHS recommends preventive drugs for HIV exposures.
Topics: Antiviral Agents; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Pyridines; United States; United States Public Health Service; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1999 |
Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Psoriasis; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Data and safety monitoring in the Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Zalcitabine; Zidovudine | 1999 |
Relevance of AIDS treatment with two nucleoside analogues alone.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Survival Rate; Zalcitabine; Zidovudine | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine | 1999 |
Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine.
Topics: Anti-HIV Agents; Cell Division; Cells, Cultured; DNA; Drug Resistance, Multiple; Genes, MDR; HIV Reverse Transcriptase; Humans; Nucleosides; Reverse Transcriptase Inhibitors; Thymidine Kinase; U937 Cells; Zalcitabine; Zidovudine | 1999 |
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; CD4-CD8 Ratio; Choice Behavior; Cognition; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Statistics, Nonparametric; Zalcitabine; Zidovudine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Topics: Catalytic Domain; Cytidine Triphosphate; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Lamivudine; Mutation; Proline; Reverse Transcriptase Inhibitors; Thionucleosides; Thiophenes; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 2000 |
Current laboratory assays and in vitro intracellular Th1 and Th2 cytokine synthesis in monitoring antiretroviral therapy of pediatric HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Saquinavir; Th1 Cells; Th2 Cells; Viral Load; Zalcitabine; Zidovudine | 2000 |
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Genes, pol; Genotype; HIV-1; Humans; Lamivudine; Point Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Interleukin-2; Kinetics; Lymphoid Tissue; Male; Middle Aged; RNA, Viral; Saquinavir; Viremia; Zalcitabine; Zidovudine | 1998 |
Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Spain; Zalcitabine; Zidovudine | 1999 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Bacteremia; Community-Acquired Infections; Cross Infection; Didanosine; Drug Therapy, Combination; Female; Humans; Incidence; Male; Prospective Studies; Risk Factors; Viral Load; Zalcitabine; Zidovudine | 2000 |
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
Using conditional logistic regression to fit proportional odds models to interval censored data.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biometry; CD4 Lymphocyte Count; Drug Therapy, Combination; Humans; Likelihood Functions; Models, Statistical; Regression Analysis; Statistics, Nonparametric; Survival Analysis; Zalcitabine; Zidovudine | 2000 |
Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system.
Topics: Abnormalities, Drug-Induced; Animals; Anti-HIV Agents; Crown-Rump Length; Didanosine; Drug Therapy, Combination; Embryo, Mammalian; Female; HIV Protease Inhibitors; Indinavir; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; Zalcitabine; Zidovudine | 2000 |
Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster.
Topics: Animals; Cytarabine; Dideoxyadenosine; Directed Molecular Evolution; Drosophila melanogaster; Enzyme Activation; Feedback; Inhibitory Concentration 50; Kinetics; Mutation; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Polymerase Chain Reaction; Substrate Specificity; Thymidine; Thymine Nucleotides; Zalcitabine; Zidovudine | 2000 |
Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
Topics: Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Coculture Techniques; Cyclopropanes; HIV-1; Humans; Microglia; Neuroglia; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Topics: Cell Division; Didanosine; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; HIV-1; Humans; Hydroxyurea; Leukocytes, Mononuclear; Macrophages; Nucleosides; Resveratrol; Stilbenes; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.
Topics: Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Deoxyribonucleotides; Dideoxynucleotides; DNA; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; Exodeoxyribonucleases; Humans; Kinetics; Lamivudine; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Thymine Nucleotides; Zalcitabine; Zidovudine | 2001 |
Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
A bend in the road--implications of ACTG 175 and Delta trials.
Topics: Anti-HIV Agents; Australia; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Europe; HIV Infections; HIV-1; Humans; Survival Analysis; United States; Zalcitabine; Zidovudine | 1996 |
Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Zalcitabine; Zidovudine | 1997 |
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Seropositivity; Humans; RNA, Viral; Zalcitabine; Zidovudine | 1997 |
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Prospective Studies; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Survival Rate; Zalcitabine; Zidovudine | 1995 |
Crixivan reduces viral load.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Combination 3TC/AZT therapy shows promise.
Topics: CD4 Lymphocyte Count; Codon; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Clinical progress and transmission perils stressed at second human retroviruses conference.
Topics: Acyclovir; AIDS Vaccines; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Herpesviridae; HIV Infections; Humans; Interleukin-2; Lamivudine; Lymphoma, Non-Hodgkin; Retroviridae; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1995 |
AIDS task force grapples with faster access to protease drugs.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Drug Approval; Drug Design; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Treatment Outcome; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
AZT + 3TC: early results promising.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
New combo trial/same old style.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
3TC: the good news and the bad news.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Europe; HIV Infections; Humans; Lamivudine; United States; Zalcitabine; Zidovudine | 1995 |
Drug companies seek trial participants.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Drug Industry; Drug Therapy, Combination; HIV Protease Inhibitors; Hotlines; Humans; Patient Selection; United States; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
Lamivudine useful against hepatitis B-HIV co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Combination antiretroviral treatment: new views, evolving practices.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cells, Cultured; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Approval; Drug Combinations; Drug Therapy, Combination; Health Services Accessibility; Humans; Insurance, Health; Lamivudine; Managed Care Programs; United States; Zalcitabine; Zidovudine | 1995 |
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC: now available again up to CD4 of 300.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Drug Industry; Drug Therapy, Combination; Humans; Lamivudine; Patient Selection; United States; Zalcitabine; Zidovudine | 1995 |
A closer look at 3TC. Interview by Mark Mascolini.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Roche submits NDA for Invirase.
Topics: Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Investigational New Drug Application; Isoquinolines; Quinolines; Saquinavir; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Update on HIV protease inhibitors.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Design; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Phosphorylation; Pyridines; Quinolines; Ritonavir; Saquinavir; Substrate Specificity; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
AZT delta study: major European/Australian study finds combinations better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
3TC and saquinavir: we need them now.
Topics: Antiviral Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
Roaches of inner space.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Virulence; Virus Replication; Zalcitabine; Zidovudine | 1995 |
ACTG 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Making sense of 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Zalcitabine; Zidovudine | 1995 |
New trials reach same conclusion: two drugs are better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Study results at a glance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
FDA triple header. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
3TC/AZT: just another combination.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Lamivudine (3TC) approved for combination use with AZT.
Topics: Adult; Antiviral Agents; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
3TC approved: now for the tough questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Benefits of combination therapy confirmed.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Treatment Failure; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Potent new AIDS drugs underscore promise of combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Clinicians experiment with post-exposure drug pairs.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Zalcitabine; Zidovudine | 1996 |
Protease inhibitors shine in triple combinations.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Back to the nukes.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
A surprisingly potent nucleoside analogue.
Topics: Adult; Antiviral Agents; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
AZT and 3TC.
Topics: CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Ritonavir: first to prolong survival.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Ritonavir; Saquinavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
CDC takes aggressive stance on postexposure prophylaxis. Centers for Disease Control and Prevention.
Topics: Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Pyridines; Risk Factors; United States; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
Eradication of HIV: the cutting edge of clinical trial design.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Leukocytes, Mononuclear; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adults and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Primary Health Care; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1995 |
Association between zalcitabine therapy for human immunodeficiency virus and granuloma annulare?
Topics: Adult; Female; Granuloma Annulare; HIV Infections; Humans; Pain; Remission, Spontaneous; Zalcitabine; Zidovudine | 2001 |
Differential susceptibility of retroviruses to nucleoside analogues.
Topics: Animals; Antiviral Agents; Cell Line; Cricetinae; Didanosine; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Lamivudine; Mink; Nucleosides; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Zalcitabine; Zidovudine | 2001 |
Testing the reverse transcriptase model of somatic mutation.
Topics: Animals; Antibody Diversity; B-Lymphocytes; Female; Green Fluorescent Proteins; Immunoglobulin Variable Region; Immunoglobulins; Luminescent Proteins; Mice; Mice, Inbred C57BL; Models, Immunological; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2001 |
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis; Recombination, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2001 |
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-HIV Agents; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Follow-Up Studies; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Stavudine; Vitamin B 12; Zalcitabine; Zidovudine | 2002 |
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; Antigens, CD34; Cell Line; Didanosine; Dideoxynucleosides; Epithelial Cells; Hematopoietic Stem Cells; Humans; Kidney Tubules, Proximal; Liver; Muscle, Skeletal; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 2002 |
The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Anti-HIV Agents; Blood-Brain Barrier; Capillaries; Carbon Radioisotopes; Choroid Plexus; Chromatography, High Pressure Liquid; Diuretics, Osmotic; Guinea Pigs; Herbicides; Mannitol; Octanols; Oligopeptides; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Perfusion; Probenecid; Sodium Chloride; Tritium; Uricosuric Agents; Zalcitabine; Zidovudine | 2002 |
The dangers of inferring treatment effects from observational data: a case study in HIV infection.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Observation; Randomized Controlled Trials as Topic; Selection Bias; Zalcitabine; Zidovudine | 2002 |
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Topics: Animals; Anti-HIV Agents; Cytidine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macaca mulatta; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2002 |
An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti).
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Chimera; Cloning, Molecular; Didanosine; DNA, Complementary; Hagfishes; Kinetics; Molecular Sequence Data; Oocytes; Protein Isoforms; Recombinant Proteins; Symporters; Xenopus; Zalcitabine; Zidovudine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
[Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Depression; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Mononucleosis; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Refusal; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Viremia; Zalcitabine; Zidovudine | 2002 |
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors.
Topics: Amino Acid Sequence; Deoxycytidine Monophosphate; Diphosphates; DNA; DNA Primers; DNA Replication; Drug Resistance, Multiple, Viral; HIV Reverse Transcriptase; Humans; Lamivudine; Molecular Sequence Data; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sequence Alignment; Thymidine Monophosphate; Zalcitabine; Zidovudine | 2002 |
Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine; Zalcitabine; Zidovudine | 2002 |
Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs.
Topics: Amino Acid Sequence; Anti-HIV Agents; Baculoviridae; Binding Sites; DNA Polymerase gamma; DNA Primers; DNA-Directed DNA Polymerase; DNA, Viral; Electrophoretic Mobility Shift Assay; Humans; Lamivudine; Mitochondria; Molecular Sequence Data; Mutagenesis, Site-Directed; Polymerase Chain Reaction; Protein Conformation; Protein Folding; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Stavudine; Zalcitabine; Zidovudine | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleosides; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication; Zalcitabine; Zidovudine | 2003 |
2', 3'-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells.
Topics: Anti-HIV Agents; Blotting, Western; Cells, Cultured; Cytarabine; DNA Primers; Down-Regulation; Drug Resistance, Multiple; Gene Expression Regulation, Enzymologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes; Thymidine Kinase; Zalcitabine; Zidovudine | 2004 |
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
Topics: Analysis of Variance; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Combinations; HIV Infections; Humans; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Self-Sustained Sequence Replication; Sensitivity and Specificity; Zalcitabine; Zidovudine | 2004 |
Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions.
Topics: Adjuvants, Immunologic; Anti-HIV Agents; Cell Division; Cytokines; Drug Interactions; HIV Protease Inhibitors; Humans; Immunoglobulins; Indinavir; Leukocytes, Mononuclear; Lymphocyte Activation; Zalcitabine; Zidovudine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Sequence Data; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Virus Replication; Zalcitabine; Zidovudine | 2005 |
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Nevirapine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2006 |
Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis.
Topics: Adipocytes; Cell Culture Techniques; Cell Line; Cell Respiration; DNA, Mitochondrial; Humans; Lipids; Models, Biological; Oxygen Consumption; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2005 |
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Arginine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Organophosphonates; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2006 |
Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Cell Proliferation; Cell Shape; Dideoxynucleosides; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport; HIV-Associated Lipodystrophy Syndrome; Mice; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides; Zalcitabine; Zidovudine | 2007 |
Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Electron Transport Complex I; Humans; Phosphorylation; Reverse Transcriptase Inhibitors; Superoxides; Zalcitabine; Zidovudine | 2008 |
Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.
Topics: Animals; DNA, Mitochondrial; Drug Interactions; Electron Transport; Electron Transport Complex IV; Gene Dosage; Lactates; Lipid Peroxidation; Male; Malondialdehyde; Mice; Mice, Inbred BALB C; Mitochondrial Myopathies; Muscle, Skeletal; Reverse Transcriptase Inhibitors; Triglycerides; Uridine; Zalcitabine; Zidovudine | 2008 |
Structural studies of nucleoside analog and feedback inhibitor binding to Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Topics: Adenosine Diphosphate; Animals; Antimetabolites; Bromodeoxyuridine; Cytarabine; Cytidine Triphosphate; Drosophila melanogaster; Drosophila Proteins; Feedback; Floxuridine; Guanosine Triphosphate; Hydrogen Bonding; Inhibitory Concentration 50; Kinetics; Models, Chemical; Models, Molecular; Phosphotransferases (Alcohol Group Acceptor); Protein Binding; Protein Structure, Secondary; Structure-Activity Relationship; Thymine Nucleotides; X-Ray Diffraction; Zalcitabine; Zidovudine | 2008 |
Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues.
Topics: Administration, Oral; Animals; Anti-HIV Agents; DNA, Mitochondrial; Drug Interactions; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Mitochondrial Encephalomyopathies; Mitochondrial Myopathies; Uridine; Zalcitabine; Zidovudine | 2010 |
Transgenic cardiac-targeted overexpression of human thymidylate kinase.
Topics: Animals; Anti-HIV Agents; DNA Replication; DNA, Mitochondrial; Echocardiography; Emtricitabine; Female; Humans; Hypertrophy, Left Ventricular; Male; Mice; Mice, Transgenic; Mitochondria, Heart; Myocardium; Nucleoside-Phosphate Kinase; Nucleosides; Phosphorylation; Ventricular Function, Left; Zalcitabine; Zidovudine | 2010 |
Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria.
Topics: Animals; Anti-HIV Agents; Deoxycytidine; Male; Mitochondria, Heart; Myocardium; Nucleosides; Perfusion; Phosphorylation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Stavudine; Thymidine; Zalcitabine; Zidovudine | 2010 |
Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cardiomyopathies; Cardiotoxins; Dietary Supplements; DNA Copy Number Variations; DNA, Mitochondrial; Electron Transport Complex IV; Heart; HIV Infections; Mice; Mice, Inbred BALB C; Mitochondria, Heart; Mutation; Nucleosides; Pyrimidines; Reactive Oxygen Species; Reverse Transcriptase Inhibitors; Uridine; Zalcitabine; Zidovudine | 2010 |
The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Azides; Base Sequence; Dideoxyadenosine; Dideoxynucleosides; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutagenesis, Site-Directed; Reverse Transcriptase Inhibitors; Sequence Analysis, RNA; Zalcitabine; Zidovudine | 2011 |
The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiomyopathies; Cardiotonic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Digoxin; Female; Follow-Up Studies; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Pregnancy; Prenatal Exposure Delayed Effects; Proportional Hazards Models; Prospective Studies; Treatment Outcome; United States; Zalcitabine; Zidovudine | 2012 |
TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anti-HIV Agents; Antimetabolites, Antineoplastic; Antiviral Agents; Cell Line; Cell Nucleus; Cells, Cultured; Chickens; Cytarabine; DNA Damage; DNA Repair; DNA, Mitochondrial; Gene Deletion; Mice; Phosphoric Diester Hydrolases; Zalcitabine; Zidovudine | 2013 |
Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity.
Topics: Animals; Anti-HIV Agents; Caenorhabditis elegans; Didanosine; Dideoxynucleosides; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Drug Evaluation; Humans; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxygen Consumption; Reverse Transcriptase Inhibitors; Stavudine; Ubiquinone; Zalcitabine; Zidovudine | 2015 |
Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
Topics: Anti-HIV Agents; Crystallography, X-Ray; Didanosine; DNA-Binding Proteins; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Protein Structure, Quaternary; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2017 |
A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cell Survival; Didanosine; Female; HIV Infections; Humans; Male; Middle Aged; Receptors, CXCR4; Stavudine; T-Lymphocytes, Regulatory; Viral Load; Zalcitabine; Zidovudine | 2017 |
Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Stavudine; Zalcitabine; Zidovudine | 2022 |